<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0504233485
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SERCAND 300 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUETIAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        102.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- What SERCAND is</strong></p><p>SERCAND is a medication that belongs to a class of medicines called &quot;atypical antipsychotics&quot;. Illnesses that affect the brain, such as schizophrenia and bipolar disorder, may be due to certain chemicals in the brain being out of balance. These imbalances may cause some of the symptoms you may be experiencing. Doctors and scientists are not sure what causes these imbalances to occur. SERCAND is thought to work by regulating the imbalance of chemicals in the brain.</p><p><strong>b- What SERCAND is taken for</strong></p><ul><li>treat the symptoms of schizophrenia, such as hallucinations (hearing or seeing things which are not there), fixed false beliefs, unusual suspiciousness, or emotional withdrawal. Patients may also feel depressed, anxious or tense.</li><li>treat the symptoms of mania associated with bipolar disorder, such as aggressiveness, agitation, impulsive behaviour or excessively elevated mood.</li></ul><p>&nbsp;</p><p>Your doctor may have prescribed SERCAND for another reason. Ask your doctor if you have any questions about why SERCAND has been prescribed for you. SERCAND is not a cure for your condition but it can help manage your symptoms and help you feel better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take SERCAND</strong></p><p>Do not take SERCAND if you have had an allergic reaction to SERCAND or any of the ingredients listed in the &ldquo;nonmedical ingredients&rdquo; section of this leaflet.</p><p><strong>b- Take special care with SERCAND</strong></p><p>Studies with various medications of the group to which SERCAND belongs, including SERCAND, when used in elderly patients with dementia has been associated with an increased rate of death. SERCAND is not indicated in elderly patients with dementia.</p><p><strong>Before starting SERCAND, be sure to tell your doctor:</strong></p><ul><li>if you have had an allergic reaction to any medicine which you have taken previously to treat your condition or if you think you might be sensitive or allergic to any of the ingredients in SERCAND.</li><li>about any other medications - prescription, non- prescription or alternative - that you are taking or plan to take. Certain medications can seriously affect the way other medications work.</li><li>if you are pregnant or plan to become pregnant while taking SERCAND.</li><li>if you are breast-feeding or are planning on breast- feeding while taking SERCAND. You should not breast-feed while taking SERCAND.</li><li>if you drink alcohol or use street drugs.</li><li>if you have any health problems.</li><li>if you have any heart problems and/or low blood pressure or have had a stroke.</li><li>if you have a history of seizures.</li><li>if you have diabetes, a family history of diabetes or high blood sugar during pregnancy.</li><li>if you have a history of liver or kidney problems.</li><li>if you know that you had a low white blood cell count in the past which may or may not have been caused by other medicines.</li><li>if you exercise vigorously or work in hot or sunny places.</li><li>If you already have diabetes, you should be monitored for worsening of your diabetes.</li></ul><p>&nbsp;</p><p><strong>c- Taking SERCAND with other medicines, herbal or dietary supplements</strong></p><p>Because certain medications can seriously affect the way other medications work, it is important to tell all doctors, dentists, and pharmacists who are treating you that you are taking SERCAND. As well, be sure to tell them about any other medications &ndash; prescription, non-prescription or alternative &ndash; that you are taking or plan to take.<br />You should tell your doctor if you are taking or about to stop taking medications for anxiety, or depression or to help you sleep.</p><p>Dopamine agonists, e.g. levodopa (antiparkinsonian agent), may decrease the effect of SERCAND.</p><p>Medications known to interact with SERCAND include carbamazepine (anticonvulsant), phenytoin (anticonvulsant), ketoconazole (antifungal), and protease inhibitors (for treating Human Immunodeficiency Virus). You should tell your doctor if you are taking erythromycin (antibiotic), clarithromycin (antibiotic), diltiazem, verapamil, nefazodone, thioridazine (antipsychotic), or blood pressure medications.</p><p>You should tell your doctor if you are taking erythromycin (antibiotic), clarithromycin (antibiotic), diltiazem, verapamil, nefazodone, thioridazine (antipsychotic), or blood pressure medications.</p><p>&nbsp;</p><p><strong>d- Taking SERCAND with food and drink</strong></p><p>You may take SERCAND with or without food.</p><p>You should not drink alcohol while taking SERCAND, as the combination could increase the effects of the alcohol.</p><p>&nbsp;</p><p><strong>e- Pregnancy and breast-feeding</strong></p><p>SERCAND should not be used during pregnancy unless the expected benefits to the mother markedly outweigh the potential risks to the fetus.</p><p>Neonates exposed to antipsychotic drugs including SERCAND during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases&nbsp;neonates have required intensive care unit support and prolonged hospitalization.</p><p>In some cases, babies born to a mother taking SERCAND during pregnancy have experienced symptoms of withdrawal that are severe and require the newborn to be hospitalized. Sometimes, the symptoms may resolve on their own. Be prepared to seek immediate emergency medical attention for your newborn if they have difficulty breathing, are overly sleepy, have muscle stiffness, or floppy muscles (like a rag doll), are shaking, or are having difficulty feeding.</p><p><br /><strong>f- Driving and using machines</strong></p><p>Do not drive or operate machinery until you know your response to this medication, as SERCAND can cause drowsiness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SERCAND is not recommended for use in patients under 18 years old.</strong></p><p><br /><strong><u>Usual adult dose</u></strong></p><p>In order for SERCAND to help you feel better, it is very important to take it every day exactly as your doctor tells you to. Take the exact number of tablets your doctor has prescribed at the right time every day.</p><p>It takes time to feel better and you should expect some symptoms to improve slowly over the first few weeks of treatment. Do not stop taking SERCAND, or change the times of day you take SERCAND, without talking to your doctor first.</p><p>To make sure you are getting the most benefit from SERCAND, you must:</p><ul><li>Continue taking SERCAND every day and,</li><li>Keep your doctor well informed of how you are feeling, both good and bad.</li></ul><p>By doing these two things, you and your doctor together will be able to make sure that you are getting the best dose of SERCAND for you.</p><p>Do not give SERCAND to anyone else. Your doctor has prescribed SERCAND for you only.</p><p><u><strong>Recommended Dose:</strong></u></p><p>Your dose will be titrated based on your clinical response and tolerability.</p><p><u><strong>Schizophrenia:</strong></u></p><p>The usual starting dose is 25 mg, twice daily. The recommended dose range is 50 to 800 mg/day, taken twice daily.</p><p><u><strong>Bipolar Mania:</strong></u><br />The usual starting dose is 50 mg, twice daily. The recommended dose range is 100 to 800 mg/day, taken twice daily.</p><p>&nbsp;</p><p><u><strong>b- If you forget to take SERCAND</strong></u></p><p>If you miss a dose by only a few hours, take it as soon as possible. If most of the day has passed since your missed dose, skip that dose and wait until your next scheduled dose. Never take two doses at once.</p><p>If you stop taking SERCAND abruptly you may experience withdrawal symptoms such as insomnia (inability to sleep), nausea, and vomiting.</p><p>Here are some tips that can help you remember to take each dose of SERCAND:</p><ul><li>Take your SERCAND at the same time every day;</li><li>Take SERCAND during daily events which will help you remember to take your medicine as well, e.g., mealtime or bedtime;</li><li>Use a pill container that will separate your SERCAND doses by the day of the week;</li><li>Use a calendar to note the day and time after you have taken each dose to help you keep track of when you need to take your SERCAND;</li><li>Keep a written reminder to take your SERCAND that can be easily seen, e.g., on a mirror or on the refrigerator;</li><li>Have a family member or friend remind you to take your medication.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like any medication, SERCAND may produce side effects in some people.</p><p>Increases in blood glucose (sugar) and hyperglycemia (high blood sugar) have been observed with SERCAND. Also, occasional cases of diabetes have been reported.</p><p>Light-headedness and dizziness (symptoms of postural hypotension) and drowsiness are among the most common side effects you may experience while taking SERCAND, particularly during the first week of treatment or after an increase in dose. The dizziness and drowsiness are usually mild and should go away with time. To help prevent these feelings, be careful to move slowly when you are getting up from a sitting or lying position.</p><p>Discontinuation symptoms which occur upon stopping SERCAND have been reported very commonly and include insomnia (inability to sleep), nausea, headache, diarrhea, vomiting, dizziness, and irritability. These symptoms usually go away after 1 week from your last dose.</p><p>Other common side effects may include: headache, rapid heartbeat, constipation, indigestion, dry mouth, feeling weak, swelling of arms and legs, fainting, stuffy nose, upset stomach or abdominal pain, blurred vision, some weight gain, and changes in laboratory tests for liver and thyroid functions.</p><p>As feelings of drowsiness are also common at the start of treatment, or when your dose is increased, if you have to drive, operate machinery or do anything else that requires you to be fully alert, use extra caution until you are sure SERCAND does not cause you to be drowsy.</p><p>There have been uncommon cases of difficulty swallowing and disturbance in speech and language. There have also been reports, in a small number of patients, of changes to the lens of the eye. Although it is not known whether or not these changes are caused by SERCAND, your doctor may advise you that a specific type of eye exam is recommended in order to maximize safe use of this drug.</p><p>In very rare cases, this type of medicine can interfere with your body&#39;s ability to control body temperature. Therefore, take care to avoid becoming overheated or dehydrated (for example with vigorous exercise, or exposure to extreme heat) while taking SERCAND.</p><p>The following may also occur with SERCAND, and may be seen in routine blood testing:</p><p>Decrease in the amount of white blood cells. These changes will normally disappear when stopping the treatment of SERCAND.</p><ul><li>Increase in one type of white blood cells (eosinophilia) which is sometimes seen in allergic reactions.</li><li>Increase in the amount of liver enzymes. These changes will normally disappear when continuing the treatment of SERCAND.</li><li>Increase in the amount of fatty substances (lipid levels, such as triglycerides and cholesterol) in the blood.</li><li>Increase in the amount of &lsquo;creatine phosphokinase&rsquo;, a substance in the muscles.</li><li>Increase in the amount of sugar (glucose) in the blood.</li></ul><p>One of the most important things for you to do to minimize the risks from side effects, while helping SERCAND work for you, is to contact your doctor or pharmacist if you notice any symptom that worries you, even if you think it is not connected with this medicine or is not listed here.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" rowspan="2"><p><strong>Symptom</strong><strong> </strong><strong>/ effect</strong></p></td><td colspan="2"><p><strong>Talk</strong><strong> &nbsp;with your</strong></p><p><strong>doctor</strong><strong> </strong><strong>right</strong><strong> away</strong></p></td><td rowspan="2"><p><strong>Stop</strong></p><p><strong>taking</strong><strong> </strong><strong>drug</strong><strong> </strong><strong>and</strong><strong> </strong><strong>call</strong><strong> </strong><strong>your</strong><strong> </strong><strong>doctor</strong><strong> </strong><strong>or pharmacist right away</strong></p></td></tr><tr><td><p><strong>Only</strong><strong> </strong><strong>if severe</strong></p></td><td><p><strong>In</strong><strong> </strong><strong>all</strong><strong> </strong><strong>cases</strong></p></td></tr><tr><td rowspan="3"><p><strong>Uncommon</strong></p></td><td><p>Symptoms of allergic reactions such as, skin lumps, bumps or swelling</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p>Restless legs (unpleasant sensations in the legs)</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Seizure (i.e. loss of consciousness with uncontrollable shaking &ldquo;fit&rdquo;)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td rowspan="3"><p><strong>Rare</strong></p></td><td><p>Long-lasting and painful erection)</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fever, muscle stiffness, marked increase in blood pressure and/or heartbeats, and reduced consciousness</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle twitching or abnormal movements of your face and tongue</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Very<strong> </strong>rare</strong></p></td><td><p>Anaphylaxis (severe form of allergic reaction; may include severe difficulty breathing and shock)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr></tbody></table><p>This is not a complete list of side effects. For any unexpected effects while taking SERCAND, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach of children.<br />- Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is Quetiapine Fumarate.</li><li>The other ingredients are colloidal silicon dioxide, croscarmellose sodium, ethylcellulose 7FP, fumaric acid, hydroxypropyl cellulose type LF, hydroxypropyl methylcellulose 2910 E5, magnesium stearate, polyethylene glycol 8000, red ferric oxide (25 mg only), titanium dioxide, yellow ferric oxide (25 mg and 100 mg only).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tablets of 25 mg, 100 mg, 200 mg, and 300 mg.

SERCAND Tablets 25 mg: Each peach, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “25” on the other side contains 25 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 20 tablets.

SERCAND Tablets 100 mg: Each yellow, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “100” on the other side contains 100 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 60 tablets.

SERCAND Tablets 200 mg: Each white, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “200” on the other side contains 200 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 60 tablets.

SERCAND Tablets 300 mg: Each white, capsule shaped, biconvex film-coated tablet, engraved “APO” on one side “QUE300” on the other side contains 300 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 30 tablets.

* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 06/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>أ- ما هو سيركاند</strong></p><p>ينتمي عقار سيركاند إلى مجموعة من العقاقير تُعرف بمضادات الذهان اللا نمطية.</p><p>وبعض الأمراض التي تصيب المخ؛ كداء الانفصام أو الاضطراب ثنائي القطب، قد تنتج عن اضطراب توازن بعض المواد الكيميائية بالمخ، مما قد يتسبب في ظهور بعض الأعراض التي تعاني أنت منها. ولا يزال السبب وراء هذه الاضطرابات غير معروف لدى الأطباء والعلماء. ويعمل عقار سيركاند على إعادة توازن هذه المواد الكيميائية بالمخ.</p><p>&nbsp;</p><p><strong>ب- ما هي دواعي استعماله</strong></p><p>يستخدم عقار سيركاند في:</p><p>- علاج أعراض الانفصام؛ مثل الهلوسة (سماع أو رؤية أشياء غير حقيقية) أو المعتقدات الزائفة أو الشك غير المبرر أو الانسحاب العاطفي، وقد يشعر المريض أيضا بالاكتئاب أو القلق أو التوتر.<br />&nbsp;<br />- علاج أعراض الهوس المصاحبة للاضطراب ثنائي القطب؛ مثل العدوانية والهياج والسلوك الاندفاعي أو فرط ارتفاع المزاج وقد يقوم طبيبك المعالج بوصف عقار سيركاند لأغراض أخرى. لذا، يرجى الرجوع إلى طبيبك المعالج إذا كانت لديك أية استفسارات تتعلق بأسباب وصف الدواء لحالتك.&nbsp;</p><p>ولا يعمل عقار سيركاند على علاج حالتك المرضية، ولكنه يساعد في علاج الأعراض التي تعاني منها، كما يساعدك على الشعور بالتحسن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- متى يجب عدم استخدام سيركاند</strong></p><p>لا تستخدم عقار سيركاند إذا كنت تعاني من فرط حساسية له أو لأي من المكونات المذكورة بجزئية &quot;المكونات غير الطبية&quot; بالنشرة.</p><p>&nbsp;</p><p><strong>ب- الاحتياطات عند استخدام سيركاند</strong></p><p>أسفرت الدراسات التي أجريت على مجموعة العقاقير التي ينتمي إليها عقار سيركاند عن ارتفاع معدل الوفيات عند استخدام هذه العقاقير لعلاج مرضى الخرف من كبار السن. لذا، فإنه لا ينصح باستخدام عقار سيركاند لعلاج كبار السن المصابين بالخرف.</p><p>تأكد من معرفة طبيبك المعالج بما يلي:</p><p>- إذا كنت قد أصبت بتفاعلات أرجية لدواء قد تناولته في السابق لعلاج حالتك المرضية أو إذا ساروك الشك في كونك تعاني من فرط حساسية لأي من مكونات عقار سيركاند</p><p>- أية عقاقير أو وصفات طبية أو غير طبية تقوم بتناولها أو تنتوي تناولها، حيث أن بعض العقاقير قد تؤثر في آلية عمل العقاقير الأخرى بشكل كبير</p><p>- إذا كنت حبلى أو ترغبين في ذلك أثناء تناولك لعقار سيركاند</p><p>- إذا كنت تقومين بإرضاع طفلك من الثدي أو ترغبين في ذلك أثناء تناول عقار سيركاند. فلا ينبغي تناول هذا الدواء خلال فترة الرضاعة من الثدي.</p><p>- إذا كنت تتعاطى الكحوليات أو المخدرات</p><p>- إذا كنت تعاني من أية مشكلات صحية أخرى</p><p>- إذا كنت مصابا بأية أمراض قلبية و/ أو انخفاض بضغط الدم أو إذا كنت قد أصبت بسكتة دماغية في السابق</p><p>- إذا كنت قد سبقت لك الإصابة بتشنجات</p><p>- إذا كنت تعاني من داء السكري أو إذا كان لديك تاريخا مرضيا لداء السكري بالعائلة أو إذا كنت تعاني من ارتفاع مستوى السكر بالدم أثناء الحمل</p><p>- إذا كنت قد سبقت لك الإصابة بأية مشكلات بالكبد أو الكلى</p><p>- إذا كنت قد سبقت لك الإصابة بنقص كرات الدم البيضاء بالدم؛ سواء كان ذلك متعلقا باستخدام بعض العقاقير أم لا</p><p>- إذا كنت تمارس الرياضة العنيفة أو تعمل في أجواء حارة أو في أماكن مشمسة</p><p>- إذا كنت مصابا بداء السكري، ينبغي مراقبة حالتك عن قرب، حيث أنك قد تتعرض لتدهور حالة السكري لديك.</p><p>&nbsp;</p><p><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية</strong></p><p>نظرا لأن بعض العقاقير قد تؤثر كثيرا في طريقة عمل العقاقير الأخرى، فإنه من الضروري أن تخبر جميع الأطباء المعالجين لحالتك وأطباء الأسنان والصيادلة بأنك تقوم بتناول عقار سيركاند. وتأكد أيضا من أنك قد أخبرتهم بأية عقاقير أخرى تتناولها أو تنتوي تناولها؛ سواء بوصفة طبية أو بدون أو بدائل الدواء.</p><p>وينبغي عليك أيضا أن تخبر طبيبك المعالج إذا كنت تتناول أو تنوي التوقف عن تناول العقاقير المستخدمة لعلاج القلق أو الاكتئاب أو تلك التي تساعدك على النوم.&nbsp;</p><p>قد تقلل العقاقير المحفزة للدوبامين من تأثير عقار سيركاند؛ كعقار ليفودوبا (عقار مضاد للباركنسونية).</p><p>ومن العقاقير التي تتداخل مع عقار سيركاند: عقار كاربامازيبين (مضاد للتشنجات) وعقار فينيتوين (مضاد للتشنجات) وعقار كيتوكونازول (مضاد للفطريات) ومثبطات إنزيم البروتييز (وتستخدم لعلاج فيروس نقص المناعة البشرية).</p><p>وينبغي عليك أن تخبر طبيبك المعالج إذا كنت تتناول عقار إيريثروميسين (مضاد حيوي) أو عقار كلاريثروميسين (مضاد حيوي) أو عقار ديلتيازيم أو فيراباميل أو نيفازودون أو ثيوريدازين (مضاد للذهان) أو العقاقير الخافضة لضغط الدم.</p><p>&nbsp;</p><p><strong>د- تناول سيركاند مع الطعام والشراب</strong></p><p>يمكنك تناول الدواء مع الطعام أو بدونه.</p><p>ينبغي عليك أن تتوقف عن تناول الكحوليات خلال فترة تناول عقار سيركاند، حيث أن الجمع بينهما قد يزيد من آثار الكحول على الجسم.</p><p>&nbsp;</p><p><strong>هـ - الحمل والرضاعة</strong></p><p>سيركاند لا ينبغي أن يستخدم أثناء الحمل إلا إذا كانت الفوائد المتوقعة للأم تفوق بشكل ملحوظ المخاطر المحتملة على الجنين.</p><p>حديثي الولادة المعرضين للعقاقير المضادة للذهان بما في ذلك الكيوتيابين خلال الربع الثالث من الحمل معرضون لخطر خارج الهرمية و / أو أعراض الانسحاب بعد الولادة. كانت هناك تقارير من الإثارة، فرط التوتر، نقص التوتر، ورعاش، ونعاس، وضيق في التنفس واضطراب التغذية في حديثي الولادة. وقد اختلفت هذه المضاعفات في الشدة، في حين كانت الأعراض في بعض الحالات ذاتية الحدود، وفي حالات أخرى قد يتطلب حديثي الولادة الدخول لوحدة العناية المركزة والرعاية والعلاج في المستشفيات لفترات طويلة.</p><p>في بعض الحالات، الأطفال الذين يولدون من أم تأخذ سيركاند أثناء الحمل لديهم أعراض الانسحاب التي هي حادة ويحتاج الأطفال حديثي الولادة إلى المستشفى. في بعض الأحيان، الأعراض تنحل من تلقاء نفسها. يجب ان تكون على استعداد لالتماس الرعاية الطبية الطارئة الفورية لحديثي الولادة إذا كان لديهم صعوبة في التنفس، النعاس المفرط، لديهم تصلب العضلات، أو العضلات المرنة (مثل دمية خرقة)، والهز، أو يواجهون صعوبة في الرضاعة.</p><p>&nbsp;</p><p><strong>و- تأثيره على القيادة واستخدام الآلات</strong></p><p>لا تقوم بممارسة القيادة أو تشغيل الماكينات حتى تتأكد من استجابة جسمك للدواء، حيث أن عقار سيركاند قد يتسبب في شعورك بالدوخة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا ينصح باستخدام عقار سيركاند للمرضى الأقل من 18 عاما.</strong></p><p>&nbsp;</p><p><strong>كيفية استخدام سيركاند</strong></p><p>لكي تشعر بكامل تأثير عقار سيركاند، ينبغي عليك أن تتناوله كل يوم على الوجه الذي يصفه لك طبيبك المعالج. لذا، ينبغي عليك أن تتناول جميع الأقراص الموصوفة في موعدها الصحيح كل يوم.</p><p>وسوف تحتاج لبعض الوقت كي تشعر بالتحسن، فبعض الأعراض قد تتحسن ببطء على مدار البضعة أسابيع الأولى للعلاج. فلا تتوقف عن تناول الدواء، ولا تغير من مواعيد تناوله باليوم دون الرجوع إلى طبيبك المعالج.</p><p>&nbsp;</p><p>وللحصول على أفضل تأثير لعقار سيركاند:</p><p>- استمر في تناول الدواء كل يوم.</p><p>- تواصل مع طبيبك المعالج وأبلغه بما تشعر به من أعراض سواء جيدة أو سيئة.</p><p>وبذلك، يمكنكما؛ أنت وطبيبك المعالج، التأكد من الوصول إلى الجرعة المثلى لعقار سيركاند.</p><p>لا تصف عقار سيركاند لغيرك، فقد وصفه الطبيب لك أنت فقط.</p><p>&nbsp;</p><p><strong>الجرعة الموصى بها:</strong><br />يتم معايرة جرعتك بناء على استجابتك السريرية و مدى تحملك.</p><p>&nbsp;</p><p><strong>الفصام:</strong></p><p>الجرعة المعتادة هي البداية ۲٥ ملجم، مرتين يوميا. نطاق الجرعة الموصى بها هي ٥۰ -&nbsp;۸۰۰ ملجم / يوم، وتؤخذ مرتين&nbsp;يوميا.</p><p>&nbsp;</p><p><strong>هوس القطبين:</strong><br />الجرعة المعتادة هي البداية ٥۰ ملجم، مرتين يوميا. نطاق الجرعة الموصى بها هي ۱۰۰ -&nbsp;۸۰۰ ملجم / يوم، وتؤخذ مرتين يوميا.</p><p>&nbsp;</p><p><strong>أ- الجرعة الزائدة</strong></p><p>في حال تناول جرعة مفرطة من الدواء أو إذا ساورك الشك في أنك تشكو من أية آثار جانبية شديدة لعقار سيركاند (وبخاصة النعاس وتسارع النبض والدوار والدوخة، وبخاصة عند الوقوف أو النهوض من الفراش بسرعة)، لا تتردد في الاتصال بطبيبك المعالج أو بمركز معالجة السموم على الفور أو التوجه لأقرب غرفة طواريء بأية مستشفى مباشرة. ولا تنس أخذ زجاجة الدواء معك.</p><p>&nbsp;</p><p><strong>ب- نسيان تناول جرعة سيركاند</strong></p><p>إذا نسيت أن تتناول جرعة ما، يمكنك تناولها خلال بضع ساعات من تذكرها. أما إذا مر أغلب اليوم ولم تتناول جرعتك، فقم بإسقاط الجرعة وانتظر حتى موعد الجرعة التالية من اليوم التالي. ولا تتناول جرعتين مرة واحدة أبدا.&nbsp;</p><p>&nbsp;</p><p><strong>وللمساعدة على تذكر موعد تناول الجرعة:</strong></p><p>- قم بتناول الجرعة في نفس الوقت كل يوم.</p><p>- تناول الجرعة في أوقات مميزة باليوم تساعدك على تذكرها؛ كأن تتناولها مع الوجبات أو عند النوم.</p><p>- يمكنك استخدام وعاء مخصص لتوزيع جرعات الدواء على أيام الأسبوع من خلال خانات محددة لكل يوم</p><p>- يمكنك استخدام نتيجة لتسجيل اليوم والموعد الذي قد تناولت به كل جرعة لمساعدتك على تتبع مواعيد تناول الدواء.</p><p>- يمكنك الاحتفاظ برسالة مكتوبة تذكرك بموعد تناول الجرعة في مكان واضح؛ كأن تكتبها على المرآة أو الثلاجة.</p><p>- يمكنك الاستعانة بأحد أفراد عائلتك أو أصدقائك لكي يذكرك بموعد تناول الجرعة.</p><p>وعند التوقف المفاجيء عن تناول عقار سيركاند، تكون عرضة لحدوث بعض أعراض الامتناع مثل الأرق (عدم القدرة على النوم) أو الغثيان أو القيء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>حاله حال أي عقار آخر، فقد يتسبب عقار سيركاند في إحداث بعض الآثار الجانبية لدى بعض المرضى.</p><p>فقد لوحظ حدوث ارتفاع بسكر الدم أثناء استخدام عقار سيركاند. كما تقرر أيضا ظهور بعض الحالات المتفرقة لداء السكري.</p><p>وتعد الدوخة والدوار (وهي أعراض لانخفاض ضغط الدم الوضعي) والميل للنعاس من بين أكثر الآثار الجانبية شيوعا، وبخاصة خلال الأسابيع الأولى من العلاج أو عند زيادة الجرعة. وعادة ما تكون أعراض الدوخة والدوار بسيطة وتختفي مع الوقت. ولكي تتجنب الشعور بتلك الأعراض، عليك أن تتحرك ببطء عند الوقوف بعد الجلوس أو عند النهوض من الفراش.&nbsp;</p><p>كما تقرر حدوث أعراض شائعة عند التوقف عن تناول الدواء؛ وتشمل الأرق (عدم القدرة على النوم) والغثيان والقيء والصداع والإسهال والدوخة والتهيج. وعادة ما تختفي هذه الأعراض خلال أسبوع من التوقف عن تناول آخر جرعة.<br />وتتضمن الآثار الجانبية الأخرى؛ الصداع وتسارع النبض والإمساك وعسر الهضم وجفاف الفم والشعور بالوهن وتورم الذراعين والساقين والإغماء وانسداد الأنف واضطرابات المعدة وآلام بالبطن وتشوش الرؤية وزيادة الوزن وبعض التغيرات البفحوصات المخبرية لوظائف الكبد والغدة الدرقية.</p><p>ونظرا لشيوع أعراض الميل للنعاس عند بدء تناول العلاج أو عند زيادة الجرعات، عليك أن تتوخى الحذر عند القيادة أو تشغيل الماكينات أو عند القيام بأية مهام تتطلب اليقظة. ينبغي عليك أن تحتاط بشدة حتى تتأكد من أن الدواء لا يسبب لك النعاس.&nbsp;</p><p>وقد لوحظت بعض الحالات غير الشائعة لصعوبة البلع واضطراب النطق والكلام.</p><p>كما تقرر أيضا حدوث بعض الحالات القليلة لظهور تغيرات بعدسة العين. وبرغم عدم ثبوت علاقة سببية بين استخدام عقار سيركاند وظهور هذه التغيرات، إلا أن طبيبك المعالج قد يطلب منك إجراء فحص خاص للعين لتوفير مزيد من الأمان أثناء استخدام هذا الدواء.</p><p>وفي بعض الحالات النادرة جدا، قد يتسبب هذا الدواء في اضطراب تحكم الجسم بدرجة الحرارة. لذا، ينبغي عليك التنبه لتجنب حدوث حمى مفرطة أو جفاف خلال فترة تناول عقار سيركاند (كما هو الحال عند ممارسة المجهود العنيف أو التعرض للحرارة الشديدة). &nbsp;</p><p>&nbsp;</p><p><strong>وقد تتعرض لحدوث ما يلي خلال فترة استخدامك للدواء:</strong></p><p>- نقص عدد كرات الدم البيضاء، وسوف تختفي هذه التغيرات عند التوقف عن تناول العلاج</p><p>- زيادة نوع من كرات الدم البيضاء (كثرة اليوزينيات)، ويحدث ذلك أحيانا مع بعض التفاعلات الأرجية</p><p>- ارتفاع إنزيمات الكبد، وسوف تختفي هذه التغيرات تلقائيا عند التوقف عن تناول العلاج</p><p>- زيادة المواد الدهنية بالدم (مستويات الدهون الثلاثية والكولسترول)</p><p>- زيادة مستوى الكرياتين فوسفوكيناز؛ وهي مادة موجودة بالعضلات</p><p>- زيادة مستوى السكر بالدم</p><p>ولكي تقلل من مخاطر حدوث الآثار الجانبية مع الاحتفاظ بتأثير الدواء، عليك أن تخبر طبيبك المعالج أو الصيدلي إذا ما أقلقك ظهور أية أعراض، حتى وإن ظننت أنها لا تتعلق بالدواء أو لم يتم ذكرها بهذه النشرة.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td colspan="2" rowspan="2"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب المعالج</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب المعالج</strong></p></td></tr><tr><td><p dir="RTL"><strong>فقط إذا<br />كانت<br />الأعراض<br />شديدة</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="3" colspan="1"><p dir="RTL"><strong>غير شائعة</strong></p></td><td><p dir="RTL">أعراض التفاعلات الأرجية كظهور كتل أو نتوءات بالجلد أو تورم</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td><p dir="RTL">اضطراب الساقين (شعور مزعج بالساقين)</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>تشنجات (أي فقدان الوعي المصحوب بارتجاجات بالجسم لا يستطيع المريض التحكم فيها)</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>✔</p></td></tr><tr><td rowspan="3" colspan="1"><p dir="RTL"><strong>نادرة</strong></p></td><td><p dir="RTL">انتصاب مستمر ومؤلم</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">حمى وتصلب بالعضلات وارتفاع مفرط بضغط الدم و/ أو تسارع بالنبض وانخفاض مستوى الوعي</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>وخز بالعضلات أو حركات لا إرادية بالوجه&nbsp;واللسان</p></td><td>&nbsp;</td><td><p>✔</p></td><td>&nbsp;</td></tr><tr><td colspan="1"><p><strong>نادرة<br />جدا</strong></p></td><td>تفاعلات تأقية شديدة الحساسية (صورة شديدة من التفاعلات الأرجية؛ قد تتضمن حدوث ضيق شديد بالتنفس<br />وصدمة)</td><td>&nbsp;</td><td>&nbsp;</td><td><p>✔</p></td></tr></tbody></table><p>هذه ليست القائمة الكاملة للآثار الجانبية، لذا، عند شعورك بأية آثار غير متوقعة أثناء تناول عقار سيركاند، لا تتردد في الاتصال بطبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدًا عن متناول الأطفال.<br />- يحفظ بدرجة حرارة أقل من ۳۰ درجة حرارة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>&nbsp;المادة الفعالة هي كيتيابين فيوميريت.</li><li>باقي المواد هي ثاني أكسيد السيليكون الغرواني، كروسكارميللوز الصوديوم، إيثيل السليولوز 7FP، حمض الفيوماريك، هيدروكسي بروبيل السليولوز من النوع LF، هيدروكسي بروبيل ميثيل السليولوز 2910 E5، ستيارات الماغنيسيوم، جليكول البولي إيثيلين 8000، أكسيد الحديد الأحمر (25 ملجم فقط)، ثاني أكسيد التيتانيوم وأكسيد الحديد الأصفر (25 ملجم و 100 ملجم فقط).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر الدواء في أقراص بتركيز 25 ملجم و100 ملجم و200 ملجم و300 ملجم.</p><p><strong>أقراص سيركاند 25 ملجم:</strong> كل قرص بلون خوخي، دائرية، ثنائية التحدب، قرص مغلف، محفورة &quot;APO&quot; على جانب واحد، وعلى الجانب الآخر &quot;QUE&quot; فوق &quot;25&quot; يحتوي على 25 ملجم كيتيابين على هيئة كيتيابين فيوميريت. تتوفر الاقراص في عبوات من 30 و 100 و 500 قرص و شرائط من 20 قرص.</p><p><strong>أقراص سيركاند 100 ملجم:</strong> كل قرص بلون اصفر، دائرية، ثنائية التحدب، قرص مغلف، محفورة &quot;APO&quot; على جانب واحد، وعلى الجانب الآخر &quot;QUE&quot; فوق &quot;100&quot; يحتوي على 100 ملجم كيتيابين على هيئة كيتيابين فيوميريت. تتوفر الاقراص في عبوات من 30 و100 و 500 قرص و شرائط من 60 قرص.</p><p><strong>أقراص سيركاند 200 ملجم: </strong>كل قرص بلون ابيض، دائرية، ثنائية التحدب، قرص مغلف، محفورة &quot;APO&quot; على جانب واحد، وعلى الجانب الآخر &quot;QUE&quot; فوق &quot;200&quot; يحتوي على 200 ملجم كيتيابين على هيئة كيتيابين فيوميريت. تتوفر الاقراص في عبوات من 30 و 100 و 500 قرص و شرائط من 60 قرص.</p><p><strong>أقراص سيركاند 300 ملجم:</strong> كل قرص بلون ابيض، على شكل كبسولة، ثنائية التحدب، قرص مغلف، محفورة &quot;APO&quot; على جانب واحد، وعلى الجانب الآخر &quot;QUE300&quot; يحتوي على 300 ملجم كيتيابين على هيئة كيتيابين فيوميريت. تتوفر الاقراص في عبوات من 30 و 100 و 500 قرص و شرائط من 30 قرص.</p><p>* قد لا يتم تسويق كل التراكيز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 06/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SERCAND
Quetiapine fumarate
Quetiapine 25, 100, 200 and 300 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DOSAGE FORMS, COMPOSITION AND PACKAGING

SERCAND Tablets 25 mg: Each peach, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “25” on the other side contains 25 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 20 tablets.

SERCAND Tablets 100 mg: Each yellow, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “100” on the other side contains 100 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 60 tablets.

SERCAND Tablets 200 mg: Each white, round, biconvex, film-coated tablet, engraved “APO” on one side, “QUE” over “200” on the other side contains 200 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 60 tablets.

SERCAND Tablets 300 mg: Each white, capsule shaped, biconvex film-coated tablet, engraved “APO” on one side “QUE300” on the other side contains 300 mg quetiapine as quetiapine fumarate. Available in bottles of 30, 100 and 500 tablets and in blister packages of 30 tablets.

Composition

In addition to quetiapine fumarate, each tablet contains the excipients colloidal silicon dioxide, croscarmellose sodium, ethylcellulose 7FP, fumaric acid, hydroxypropyl cellulose type LF, hydroxypropyl methylcellulose 2910 E5, magnesium stearate, polyethylene glycol 8000, red ferric oxide (25 mg only), titanium dioxide, yellow ferric oxide (25 mg and 100 mg only).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets of 25 mg, 100 mg, 200 mg, and 300 mg packed in bottles and blisters.

* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults:</strong></p><p>Schizophrenia</p><p>SERCAND (quetiapine) is indicated for the management of the manifestations of schizophrenia. The antipsychotic efficacy of quetiapine was established in short-term (6-week) controlled inpatient trials (see Part II: CLINICAL TRIALS). The efficacy of quetiapine in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials of patients with manifestations of schizophrenia.</p><p>&nbsp;</p><p><strong>Bipolar Disorder &ndash; Mania</strong></p><p>SERCAND is indicated as monotherapy for the acute management of manic episodes associated with bipolar disorder.</p><p>The efficacy of quetiapine in bipolar disorder - mania was established in two 12-week clinical trials of bipolar patients (see Part II: CLINICAL TRIALS). The safety and effectiveness of quetiapine for long-term use, and for prophylactic use in bipolar disorder has not been evaluated.</p><p><strong>Geriatrics (&gt; 65 years of age): </strong>SERCAND is not indicated in elderly patients with dementia. See WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions Box and Special Populations.</p><p><strong>Pediatrics (&lt; 18 years of age): </strong>The safety and efficacy of SERCAND in children under the age of 18 years have not been established and its use is not recommended (see WARNINGS AND PRECAUTIONS, Special Populations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Recommended Dose and Dosage Adjustment</u></p><p>SERCAND (quetiapine fumarate) can be administered with or without food (see PHARMACOLOGICAL PROPERTIES, Pharmacokinetics).</p><p>&nbsp;</p><p><strong>Schizophrenia</strong></p><p>The usual starting dose of SERCAND (quetiapine) is 25 mg b.i.d., titrated with increments of 25- 50 mg b.i.d. per day, as tolerated, to a target dose of 300 mg/day given b.i.d. within four to seven days.</p><p>Further dosage adjustments may be indicated depending on the clinical response and tolerability in the individual patient. Dosage adjustments should generally occur at intervals of not less than 2 days, as steady state for quetiapine would not be achieved for approximately 1-2 days in the typical patient. When adjustments are necessary, dose increments/decrements of 25-50 mg b.i.d. are recommended.</p><p>Clinical trials suggest that the usual effective treatment dose will be in the range of 300-600 mg/day (see Part II: CLINICAL TRIALS). However, some patients may require as little as 150 mg/day. The safety of doses above 800 mg/day has not been evaluated.</p><p>The need for continuing existing EPS medications should be re-evaluated periodically as quetiapine has not been associated with treatment-emergent EPS across the clinical dose range.</p><p>&nbsp;</p><p><strong>Bipolar Disorder</strong></p><p><strong><em>Bipolar Mania</em></strong></p><p>Usual Dose: The titration rate, based on the clinical trials (see Part II: CLINICAL TRIALS) is shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Day</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td></tr><tr><td><p>BID</p></td><td><p>100 mg/day</p></td><td><p>200 mg/day</p></td><td><p>300 mg/day</p></td><td><p>400 mg/day</p></td><td><p>Up to 600 mg/day</p></td><td><p>Up to 800 mg/day</p></td></tr></tbody></table><p>Dosage adjustments should be made depending on the clinical response and tolerability in the individual patient.</p><p>Approximately 85% of patients responded between 400 and 800 mg/day, while over 50% of patients responded between 600 and 800 mg/day (the average median dose for responders during the last week of treatment was approximately 600 mg/day). The safety of doses above 800 mg/day has not been evaluated.</p><p>&nbsp;</p><p><strong><u>Dosing Considerations in Special Populations</u></strong></p><p><strong>Elderly: </strong>In clinical trials, 38 patients with schizophrenia or related disorders, 65 years of age or over, were treated with quetiapine (see WARNINGS AND PRECAUTIONS, Special Populations). Given the limited experience with quetiapine in the elderly, and the higher incidence of concomitant illness and concomitant medication in this population, SERCAND should be used with caution. The mean plasma clearance of quetiapine was reduced by 30% to 50% in elderly subjects when compared to younger patients. The rate of dose titration may thus need to be slower, and the daily therapeutic target dose lower, than that used in younger patients.</p><p>&nbsp;</p><p><strong>Hepatic Impairment: </strong>Quetiapine is extensively metabolized by the liver (see ACTIONS AND PHARMACOLOGY, Special Populations and Conditions). Therefore, SERCAND should be used with caution in patients with mild hepatic impairment, especially during the initial dosing period. Patients with mild hepatic impairment should be started on 25 mg/day. The dose should be increased daily in increments of 25 to 50 mg/day to an effective dose, depending on the clinical response and tolerance in the individual patient. No pharmacokinetic data are available for any dose of quetiapine in patients with moderate to severe hepatic impairment. However, should clinical judgement deem treatment with SERCAND necessary, the drug should be used with great caution in patients with moderate or severe hepatic impairment (see WARNINGS AND PRECAUTIONS, Hepatic and PHARMACOLOGICAL PROPERTIES, Special Populations and Conditions).</p><p>&nbsp;</p><p><strong>Renal Impairment: </strong>As clinical experience is lacking, caution is advised (see WARNINGS AND PRECAUTIONS, Renal).</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>If a dose is missed by only a few hours, take it as soon as possible. If most of the day has passed since the missed dose, skip that dose and wait until next scheduled dose. Never take two doses at once.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SERCAND (quetiapine) is contraindicated in patients with a known hypersensitivity to this medication or any of its ingredients. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING or section 6.1 List of excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Serious Warnings and Precautions </strong></p><p>&nbsp;</p><p><strong>Increased Mortality in Elderly Patients with Dementia</strong></p><p><strong>Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of thirteen placebo-controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6 fold increase in death rate in the drug-related patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature (see WARNINGS AND PRECAUTIONS, Special Populations, Use in Geriatric Patients with Dementia).</strong></p><p><strong>&nbsp;</strong></p><p><strong>Suicidal</strong><strong> </strong><strong>Thoughts</strong><strong> and Behaviors</strong></p><p><strong>Antidepressants</strong><strong> increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (4.4)]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (4.4)].</strong></p><p><strong>SERCAND </strong><strong>is not approved for use in pediatric patients under ten years of age.</strong></p></td></tr></tbody></table><p><strong>General</strong></p><p><strong>Body Temperature Regulation: </strong>Disruption of the body&#39;s ability to reduce core body temperature has been attributed to antipsychotic agents (including SERCAND (quetiapine fumarate)). Appropriate care is advised when prescribing SERCAND for patients who will be experiencing conditions which may contribute to an elevation of core temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. See Undesirable effects, Clinical Trial Adverse Drug Reactions, Other Adverse Events, Pyrexia.</p><p>&nbsp;</p><p><strong>Acute Withdrawal (discontinuation) Symptoms: </strong>Acute discontinuation symptoms such as insomnia, nausea, headache, diarrhea, vomiting, dizziness and irritability, have been described after abrupt cessation of antipsychotic drugs including quetiapine. Gradual withdrawal over a period of at least one to two weeks is advisable. Symptoms usually resolved after 1 week post- discontinuation.</p><p>&nbsp;</p><p><strong><u>Carcinogenesis and Mutagenesis</u></strong></p><p>For animal data, see Part II: TOXICOLOGY.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong></p><p><strong>Hypotension and Syncope: </strong>As with other drugs that have high &alpha;1&nbsp;adrenergic receptor blocking activity, quetiapine may induce orthostatic hypotension, tachycardia, dizziness, and sometimes syncope, especially during the initial dose titration period. These events may lead to falls (see UNDESIRABLE EFFECTS).</p><p>Syncope was reported in 1% (35/4083) of patients treated with quetiapine, compared with 0.3% (3/1006) on placebo, and 0.4% (2/527) on active control drugs. The risk of hypotension and syncope may be reduced by more gradual titration to the target dose (see DOSAGE AND ADMINISTRATION).</p><p>Quetiapine should be used with caution in patients with known cardiovascular disease (e.g., history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or other conditions predisposing to hypotension (e.g., dehydration, hypovolemia and treatment with antihypertensive medications) (see OVERDOSAGE). Quetiapine should be used with caution in patients with known cardiovascular disease (e.g., history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or other conditions predisposing to hypotension (e.g., dehydration, hypovolemia and treatment with antihypertensive medications) (see OVERDOSAGE).</p><p>&nbsp;</p><p><strong>QT Prolongation: </strong>In clinical trials, quetiapine was not associated with a persistent increase in absolute QT intervals. However, in post-marketing experience, there were cases reported of QT prolongation with overdose (see OVERDOSAGE). As with other antipsychotics, caution should be exercised when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation. Also caution should be exercised when quetiapine is prescribed either with medicines known to increase QT interval or with concomitant neuroleptics, especially for patients with increased risk of QT prolongation, i.e., the elderly, patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalemia, or hypomagnesemia (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p><strong>Worsening</strong><strong> of More than one Metabolic Parameter (among Cholesterol and Triglyceride Elevations; Hyperglycaemia; Weight Gain): </strong>In some patients, a worsening of more than one of the metabolic factors of weight, blood glucose and lipids was observed in clinical studies.</p><p>Changes in these parameters should be managed as clinically appropriate.</p><p>&nbsp;</p><p><strong>Cholesterol</strong><strong> and Triglyceride Elevations: </strong>Very common (&ge;10%) cases of elevations in serum triglyceride levels (&ge;2.258 mmol/L on at least one occasion), elevations in total cholesterol (predominantly LDL cholesterol) (&ge;6.2064 mmol/L on at least one occasion), and decreases in HDL cholesterol (&lt;1.025 mmol/L males; &lt;1.282 mmol/L females at any time) have been observed during treatment with quetiapine in clinical trials (see UNDESIRABLE EFFECTS). Lipid changes should be managed as clinically appropriate.</p><p>&nbsp;</p><p>In short-term placebo-controlled schizophrenia trials, quetiapine-treated patients showed mean increases from baseline in cholesterol and triglyceride of 11% and 17%, respectively, compared to mean decreases in the placebo-treated patients. LDL cholesterol was not measured in these trials.</p><p>&nbsp;</p><p><strong>Hyperglycaemia: </strong>As with some other antipsychotics, hyperglycaemia and diabetes mellitus (including exacerbation of pre-existing diabetes, diabetic ketoacidosis, and diabetic coma including some fatal cases) in the aggregate have been reported rarely (&sup3;0.01% - &lt;0.1%) during the use of quetiapine in post-marketing experience, sometimes in patients with no reported history of hyperglycaemia (see UNDESIRABLE EFFECTS, Post-Market Adverse Drug Reactions).</p><p>&nbsp;</p><p>Increases in blood glucose and hyperglycaemia, and occasional reports of diabetes, have been observed in clinical trials with quetiapine (see UNDESIRABLE EFFECTS, Abnormal Hematologic and Clinical Chemistry Findings).</p><p>&nbsp;</p><p>Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycaemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycaemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycaemia- related adverse events in patients treated with atypical antipsychotics are not available.</p><p>&nbsp;</p><p>Patients should have a baseline and periodic monitoring of blood glucose. Patients&nbsp; treated with atypical antipsychotics should be monitored for symptoms of hyperglycaemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycaemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycaemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><strong>Weight Gain: </strong>In controlled schizophrenia clinical trials (up to 6 weeks), mean weight gain was approximately 2.3 kg compared to a mean weight gain of 0.1 kilograms in patients taking placebo (n=427). In open-label extension trials, after 9 to 13 weeks of quetiapine monotherapy, the mean weight increase was 1.58 kg (n=170). After 53 to 78 weeks of treatment, the mean weight increase was 1.98 kg (n=137). These data are obtained from uncontrolled, open-label trials; the relevance of these findings to clinical practice is unknown. Weight change over time appeared to be independent of quetiapine dose (see UNDESIRABLE EFFECTS).</p><p>In the acute placebo-controlled bipolar mania clinical trials (up to 12 weeks) mean weight gain in patients taking quetiapine was 1.8 kg compared to a mean weight loss of 0.1 kg in patients taking placebo. In patients completing the entire 12 weeks of treatment mean weight gain in patients taking quetiapine was 2.8 kg.</p><p>&nbsp;</p><p>Based on the cumulative acute placebo-controlled clinical trial database, weight gain (based on &ge;7% increase in body weight from baseline) was reported in 9.6% in quetiapine-treated patients and 3.8% in placebo-treated patients, which occurs predominantly during the early weeks of treatment in adults (see UNDESIRABLE EFFECTS). Patients should have baseline and periodic monitoring of body weight.</p><p>&nbsp;</p><p><strong>Hyperprolactinemia: </strong>During clinical trials with quetiapine, elevation in prolactin levels occurred in 3.6% (158/4416) of patients treated with quetiapine compared to 2.6% (51/1968) on placebo (see UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p>Increased prolactin levels with quetiapine were observed in rat studies. As is common with compounds which stimulate prolactin release, the administration of quetiapine resulted in an increase in the incidence of mammary neoplasms in rats. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear. To date, neither clinical nor epidemiological studies have shown an association between chronic administration of drugs that stimulate prolactin release, and mammary tumourigenesis. Tissue culture experiments, however, indicate that approximately one third of human breast cancers are prolactin dependent <em>in vitro</em>; a factor of potential importance if prescription of these drugs is contemplated in a patient with previously detected breast cancer.</p><p>&nbsp;</p><p>Possible manifestations associated with elevated prolactin levels are amenorrhea, galactorrhea, and menorrhagia. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone mineral density in both female and male subjects.</p><p>&nbsp;</p><p>In the multiple fixed-dose schizophrenia clinical trial there were no differences in prolactin levels at study completion for quetiapine, across the recommended dose range, and placebo.</p><p>&nbsp;</p><p><strong>Hypothyroidism: &nbsp;</strong>Clinical trials in schizophrenia demonstrated that quetiapine is associated with a dose-related decrease in total and free thyroxine (T4). On average quetiapine was associated with about a 20% mean reduction in thyroxine levels (both total and free). Forty-two percent of quetiapine-treated patients showed at least a 30% reduction in total T4&nbsp;and 7% showed at least a 50% reduction. Maximum reduction of thyroxine levels generally occurred during the first two to four weeks of treatment with quetiapine. These reductions were maintained without adaptation or progression during longer term treatment. Decreases in T4&nbsp;were not associated with systematic changes in TSH or clinical signs or symptoms of hypothyroidism. Approximately 0.4% 12/2595) of patients treated with quetiapine (schizophrenia and bipolar mania studies combined) experienced persistent increases in TSH, and 0.25% of patients were treated with thyroid replacement. See UNDESIRABLE EFFECTS.</p><p>&nbsp;</p><p><strong><u>Gastrointestinal</u></strong></p><p><strong>Antiemetic Effect: </strong>Consistent with its dopamine antagonist effects, quetiapine may have an antiemetic effect. Such an effect may mask signs of toxicity due to overdosage of other drugs, or may mask symptoms of disease such as brain tumour or intestinal obstruction.</p><p>&nbsp;</p><p><strong>Dysphagia and Aspiration Pneumonia: </strong>Dysphagia and aspiration have been reported with quetiapine. Although a causal relationship with aspiration pneumonia has not been established, quetiapine should be used with caution in patients at risk for aspiration pneumonia. See WARNINGS AND PRECAUTIONS, Special Populations and UNDESIRABLE EFFECTS.</p><p>&nbsp;</p><p><strong>Constipation and Intestinal Obstruction: </strong>Constipation represents a risk factor for intestinal obstruction. Constipation and intestinal obstruction have been reported with quetiapine. This includes fatal reports in patients who are at a higher risk of intestinal obstruction, including those that are receiving multiple concomitant medications that decrease intestinal motility and/or may not report symptoms of constipation. See UNDESIRABLE EFFECTS, Post-Market Adverse Drug Reactions. Patients with known or suspected gastrointestinal obstruction (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus of any type) may also be at higher risk of intestinal obstruction.</p><p>&nbsp;</p><p><strong><u>Genitourinary</u></strong></p><p><strong>Priapism: </strong>Rare cases of priapism have been reported with antipsychotic use, such as quetiapine. This adverse reaction, as with other psychotropic drugs, did not appear to be dose-dependent and did not correlate with the duration of treatment.</p><p>&nbsp;</p><p><strong><u>Hematologic</u></strong></p><p><strong>Leukopenia,</strong><strong> Neutropenia and Agranulocytosis</strong></p><p><strong>&nbsp;</strong></p><p>In clinical trial and post-marketing experience, events of neutropenia, granulocytopenia and agranulocytosis (severe neutropenia with infection) have been reported during antipsychotic use, including quetiapine. It is recommended that patients have their complete blood count (CBC) tested prior to starting quetiapine and then periodically throughout treatment.</p><p>&nbsp;</p><p>Severe neutropenia (&lt;0.5 x 109/L) has been uncommonly reported in short-term placebo controlled monotherapy clinical trials with quetiapine. Most of the cases of severe neutropenia have occurred within the first two months of starting therapy with quetiapine. There was no apparent dose relationship. Neutropenia should be considered in patients presenting with infection, particularly in the absence of obvious predisposing factors(s), or in patients with unexplained fever, and should be managed as clinically appropriate. There have been rare cases of agranulocytosis among all patients treated with quetiapine during clinical trials as well as post-marketing reports (including fatal cases). There have also been cases of agranulocytosis in patients without pre-existing risk factors. Agranulocytosis has also been reported with other agents in the class (see UNDESIRABLE EFFECTS, Other Adverse Events, Post-Market Adverse Drug Reactions).</p><p>Possible risk factors for leukopenia/neutropenia include pre-existing low white cell count &nbsp;(WBC) and history of drug induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue quetiapine at the first sign of a decline in WBC in absence of other causative factors. Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt;1 x 109/L) should discontinue quetiapine and have their WBC followed until recovery (see UNDESIRABLE EFFECTS, Abnormal Hematologic and Clinical Chemistry Findings and Post-Market Adverse Drug Reactions).</p><p>&nbsp;</p><p><strong>Venous Thromboembolism: </strong>Venous thromboembolism (VTE), including fatal pulmonary embolism, has been reported with antipsychotic drugs, including SEROQUEL, in case reports and/or observational studies. When prescribing quetiapine all potential risk factors for VTE should be identified and preventative measures undertaken.</p><p>&nbsp;</p><p><strong><u>Hepatic/Pancreatic</u></strong></p><p><strong>Hepatic Impairment: </strong>Decreased clearance of quetiapine was observed in patients with mild hepatic impairment (see PHARMACOLOGICAL PROPERTIES, Special Populations and Conditions). Patients with mild hepatic impairment should be started on 25 mg/day. The dose should be increased daily in increments of 25 to 50 mg/day to an effective dose, depending on the clinical response and tolerability in the individual patient. No pharmacokinetic data are available for any dose of quetiapine in patients with moderate or severe hepatic impairment. However, should clinical judgement deem treatment with quetiapine necessary, the drug should be used with great caution in patients with moderate or severe hepatic impairment (see PHARMACOLOGICAL PROPERTIES, Special Populations and Conditions and DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Transaminase </strong><strong>Elevations: </strong>During premarketing clinical trials, therapy with quetiapine was associated with elevation of hepatic transaminases, primarily ALT. Within a clinical trial database of 1892 quetiapine-treated schizophrenia patients, with baseline ALT levels &lt;60 IU/L, 5.3% (101/1892) had treatment-emergent ALT elevations to &gt;120 IU/L, 1.5% (29/1892) had elevations to &gt;200 IU/L, and 0.2% (3/1892) had elevations to &gt;400 IU/L. No patients had values in excess of 800 IU/L. None of the quetiapine -treated patients who had elevated transaminase values manifested clinical symptomatology associated with liver impairment. The majority of transaminase elevations were seen during the first two months of treatment. Most elevations were transient (80%) while patients continued on quetiapine therapy. Of the 101 quetiapine- treated patients whose enzyme levels increased to &gt;120 IU/L, 40 discontinued treatment while their ALT values were still raised. In 114 quetiapine&ndash;treated patients whose baseline ALT was &gt;90 IU/L, only 1 experienced an elevation to &gt;400 IU/L.</p><p>&nbsp;</p><p>In the bipolar disorder - mania trials, the proportions of patients with transaminase elevations of &gt; 3 times the upper limits of the normal reference range, was approximately 1% for both quetiapine-treated and placebo-treated patients.</p><p>&nbsp;</p><p>Precautions should be exercised when using quetiapine in patients with pre-existing hepatic disorders, in patients who are being treated with potentially hepatotoxic drugs, or if treatment- emergent signs or symptoms of hepatic impairment appear.</p><p>&nbsp;</p><p>For patients who have known or suspected abnormal hepatic function prior to starting quetiapine, standard clinical assessment, including measurement of transaminase levels is recommended.</p><p>Periodic clinical reassessment with transaminase levels is recommended for such patients, as well as for patients who develop any signs and symptoms suggestive of a new onset liver disorder during quetiapine therapy (see UNDESIRABLE EFFECTS, Abnormal Hematologic and Clinical Chemistry Findings).</p><p>&nbsp;</p><p><strong>Pancreatitis: </strong>Pancreatitis has been reported in clinical trials and during post marketing experience. Among post marketing reports, while not all cases were confounded by risk factors, many patients had factors which are known to be associated with pancreatitis such as increased triglycerides (see WARNINGS and PRECAUTIONS, Endocrine and Metabolism), gallstones, and alcohol consumption.</p><p>&nbsp;</p><p><strong><u>Neurologic</u></strong></p><p><strong>Neuroleptic Malignant Syndrome (NMS): </strong>Neuroleptic Malignant Syndrome is a potentially fatal symptom complex that has been reported in association with antipsychotic drugs, including quetiapine.</p><p>The clinical manifestations of NMS are hyperthermia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.</p><p>In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system pathology.</p><p>The management of NMS should include immediate discontinuation of antipsychotic drugs, including quetiapine, and other drugs not essential to concurrent therapy; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p><p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored since recurrences of NMS have been reported.</p><p>&nbsp;</p><p><strong>Tardive Dyskinesia (TD) and Extrapyramidal Symptoms (EPS): </strong>Tardive Dyskinesia is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic drugs including quetiapine. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon estimates to predict which patients are likely to develop the syndrome.</p><p>In placebo-controlled clinical trials for schizophrenia and bipolar mania the incidence of EPS was no different from that of placebo across the recommended therapeutic dose range. It has been hypothesized that agents with a lower EPS liability may also have a lower liability to produce TD. This relationship predicts that quetiapine should have less potential than typical antipsychotic agents to induce TD in schizophrenia and bipolar mania patients.</p><p>The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p><p>There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p><p>Given these considerations, quetiapine should be prescribed in a manner that is most likely to minimize the occurrence of TD. Chronic antipsychotic treatment should generally be reserved for patients who appear to suffer from a chronic illness that is known to respond to antipsychotic drugs, and for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p><p>If signs and symptoms of TD appear in a patient on quetiapine, dose reduction or drug discontinuation should be considered. Some patients may require treatment with quetiapine despite the presence of the syndrome. The symptoms of TD can worsen or even arise after discontinuation of treatment (see UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p><strong>Seizures: </strong>In controlled schizophrenia clinical trials, there was no difference in the incidence of seizures in patients treated with quetiapine or placebo (incidence of 0.4% or 3 events per 100 patient years in patients given quetiapine, compared with 0.5% or 6.9 events per 100 patient years for placebo). Nevertheless, as with other antipsychotics, caution is recommended when treating patients with a history of seizures or with conditions associated with a lowered seizure threshold (see UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p><strong><u>Ophthalmologic</u></strong></p><p>Cataracts: The development of cataracts was observed in association with quetiapine treatment in chronic dog studies at 4 times the recommended human dose. Lens changes have also been observed in patients during long-term quetiapine treatment, but a causal relationship to quetiapine use has not been established. The possibility of lenticular changes during long-term use of quetiapine in man, thus cannot be excluded at this time. Eye examinations (e.g., slit lamp exam) prior to or shortly after initiation of treatment with quetiapine and at 6 month intervals thereafter, are recommended. If clinically significant lens changes associated with quetiapine use are observed, discontinuation of quetiapine should be considered.</p><p>&nbsp;</p><p><strong><u>Psychiatric</u></strong></p><p><strong>Suicide/</strong><strong> suicidal thoughts or clinical worsening:</strong></p><p>Schizophrenia as well as manic episodes associated bipolar disorder, can also be associated with an increased risk of suicide-related events, and thus close supervision and appropriate clinical management of high risk patients should accompany drug therapy.</p><p>&nbsp;</p><p>Patients with a history of suicide-related events are also known to be at a greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p>There is little experience with quetiapine in patients with renal impairment, except in a low (subclinical) single dose study (see PHARMACOLOGICAL PROPERTIES, Special Populations and Conditions). Quetiapine should thus be used with caution in patients with known renal impairment, especially during the initial dosing period (see DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p><strong>Pediatrics (&lt; 18 years of age): </strong>The safety and efficacy of quetiapine in children under the age of 18 years have not been established and its use is not recommended.</p><p>&nbsp;</p><p>Weight gain has been observed with atypical antipsychotic use in pediatric and adolescent patient populations. Independent of any drug-specific effects, weight gain can be associated with adverse changes in other metabolic parameters (e.g., glucose and lipid metabolism). Abnormal childhood weight and metabolic status can have adverse effects on cardiovascular outcomes in adulthood. Weight gain and adverse effects on other metabolic parameters associated with atypical antipsychotics can be more frequent or more severe in pediatric and adolescent patients than in the adult patients.</p><p>&nbsp;</p><p>Increased blood pressure (not seen in adults) occurs more frequently in quetiapine treated patients than in placebo in patients under the age of 18 years. Additionally, frequency categories for increased appetite, elevations in serum prolactin, vomiting, rhinitis and syncope were higher in patients under the age of 18 years treated with quetiapine than in adults. Increased appetite, elevations in serum prolactin, and vomiting were very common in children and adolescents, and common in adults. Rhinitis and syncope were common in children and adolescents, and uncommon in adults (see UNDESIRABLE EFFECTS, Adverse Drug Reactions in Pediatrics).</p><p>&nbsp;</p><p>Long-term safety data including cardiometabolic effects, growth, maturation and behavioural development in patients under 18 years of age has not been systematically evaluated.</p><p>&nbsp;</p><p><strong>Geriatrics</strong><strong> (</strong><strong>&ge;</strong><strong> </strong><strong>65 years of age): </strong>The number of patients 65 years of age or over, with schizophrenia or related disorders, exposed to quetiapine, during clinical trials was limited (n=38). When compared to younger patients the mean plasma clearance of quetiapine was reduced by 30% to 50% in elderly subjects. In addition, as this population has more frequent hepatic, renal, central nervous system, and cardiovascular dysfunctions, and more frequent use of concomitant medication, caution should be exercised with the use of quetiapine in the elderly patient (see DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Use in Geriatric Patients with Dementia:</strong></p><p><strong><u>Overall</u></strong><strong><u> Mortality</u></strong><strong>: </strong><strong>Elderly patients with dementia treated with atypical antipsychotic drugs showed increased mortality compared to placebo in a meta-analysis of 13 controlled trials of various atypical antipsychotic drugs. In two placebo-controlled trials with oral </strong><strong>quetiapine </strong><strong>in</strong><strong> this population, the incidence of mortality was 5.5% for </strong><strong>quetiapine</strong><strong>-treated patients compared to 3.2% for placebo-treated patients. </strong><strong>Quetiapine </strong><strong>is not indicated in elderly patients with dementia.</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong><u>Cerebrovascular adverse events</u></strong>: An increased risk of cerebrovascular adverse events has been seen in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. There is insufficient data with quetiapine to know if there is an increased risk of cerebrovascular events associated with quetiapine. An increased risk, however, cannot be excluded. Quetiapine is not indicated in patients with dementia.</p><p>&nbsp;</p><p><strong><u>Vascular disease: </u></strong>Quetiapine should be used with caution in patients with risk factors for stroke or with a history of stroke.</p><p>&nbsp;</p><p><strong><u>Dysphagia: </u></strong>Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer&rsquo;s dementia. Quetiapine and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. See WARNINGS AND PRECAUTIONS, Gastrointestinal and UNDESIRABLE EFFECTS.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Drug-Drug Interactions</u></strong></p><p>Given the primary central nervous system effects of quetiapine, quetiapine should be used with caution in combination with other centrally acting drugs.</p><p>&nbsp;</p><p>Caution should be exercised when quetiapine is used concomitantly with drugs known to cause electrolyte imbalance or to increase QT interval (see WARNINGS AND PRECAUTIONS, Cardiovascular).</p><p>&nbsp;</p><p><strong>The Effect of Quetiapine on Other Drugs</strong></p><p><em>Alcohol: </em>Quetiapine potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with psychotic disorders. Alcoholic beverages should be avoided while taking quetiapine.</p><p><em>Antihypertensive Agents: </em>Because of its potential for inducing hypotension, quetiapine may enhance the effects of certain antihypertensive agents.</p><p><em>Levodopa</em><em> and Dopamine Agonists: </em>As it exhibits <em>in vitro </em>dopamine antagonism, quetiapine may antagonize the effects of levodopa and dopamine agonists.</p><p><em>Lithium: </em>The single dose pharmacokinetics of lithium were not altered when coadministered with quetiapine.</p><p><em>Antipyrine: </em>Quetiapine did not induce the hepatic enzyme systems involved in the metabolism of antipyrine.</p><p><em>Lorazepam: </em>Quetiapine did not affect the single dose pharmacokinetics of lorazepam.</p><p><em>Divalproex: </em>Co-administration of quetiapine (150 mg bid) and divalproex (500 mg bid) increased the mean oral clearance and the mean maximum plasma concentration of total valproic acid (administered as divalproex) by 11%. These changes were not clinically relevant.</p><p>&nbsp;</p><p><strong>The Effect of Other Drugs on Quetiapine</strong></p><p><em>Hepatic Enzyme Inducers: </em>Concomitant use of quetiapine with hepatic enzyme inducers such as carbamazepine may substantially decrease systemic exposure to quetiapine. In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine given before and during treatment with carbamazepine (a known hepatic enzyme inducer), co-administration of carbamazepine significantly increased the clearance of quetiapine. This increase in clearance reduced systemic quetiapine exposure (as measured by AUC) to an average of 13% of the exposure during administration of quetiapine alone; although a greater effect was seen in some patients. As a consequence of this interaction, lower plasma concentrations can occur, and hence, in each patient, consideration for a higher dose of quetiapine, depending on clinical response, should be considered. It should be noted that the recommended maximum daily dose of SERCAND is 800 mg/day and continued treatment at higher doses should only be considered as a result of careful consideration of the benefit risk assessment for an individual patient.</p><p>Co-administration of quetiapine and another microsomal enzyme inducer, phenytoin, caused five-fold increases in the clearance of quetiapine. Increased doses of quetiapine may be required to maintain control of psychotic symptoms in patients co-administered quetiapine and phenytoin and other hepatic enzyme inducers (e.g., barbiturates, rifampicin, etc.).</p><p>The doses of quetiapine may need to be reduced if phenytoin or carbamazepine or other hepatic enzyme inducers are withdrawn and replaced with a non-inducer (e.g., sodium valproate).</p><p><em>CYP 3A4 inhibitors: </em>CYP 3A4 is the primary enzyme responsible for cytochrome P450- mediated metabolism of quetiapine. Thus, coadministration of compounds (such as ketoconazole, erythromycin, clarithromycin, diltiazem, verapamil, or nefazodone), which inhibit CYP 3A4, may increase the concentration of quetiapine. In a multiple-dose trial in healthy volunteers to assess the pharmacokinetics of quetiapine given before and during treatment with ketoconazole, co-administration of ketoconazole resulted in an increase in mean Cmax and AUC of quetiapine of 235% and 522%, respectively, with a corresponding decrease in mean oral clearance of 84%. The mean half-life of quetiapine increased from 2.6 to 6.8 hours, but the mean tmax was unchanged. Due to the potential for an interaction of a similar magnitude in a clinical setting, the dosage of quetiapine should be reduced during concomitant use of quetiapine and potent CYP 3A4 inhibitors (such as azole antifungals, macrolide antibiotics, and protease inhibitors). Special consideration should be given in elderly and debilitated patients. The risk- benefit ratio needs to be considered on an individual basis in all patients.</p><p><em>Divalproex: </em>Co-administration of quetiapine (150 mg bid) and divalproex (500 mg bid) increased the mean maximum plasma concentration of quetiapine by 17% without changing the mean oral clearance.</p><p><em>Cimetidine: </em>In a clinical study examining the pharmacokinetics of quetiapine following coadministration with cimetidine, (a non-specific P450 enzyme inhibitor), no clinically significant interaction was observed.</p><p><em>Thioridazine: </em>Coadministration of thioridazine (200 mg b.i.d.) with quetiapine (300 mg b.i.d.), increased the clearance of quetiapine by 65%.</p><p><em>Fluoxetine,</em><em> Imipramine, Haloperidol, and Risperidone: </em>Fluoxetine (60 mg daily), imipramine (75 mg b.i.d.), haloperidol (7.5 mg b.i.d.), and risperidone (3 mg b.i.d.) did not significantly alter the steady state pharmacokinetics of quetiapine.</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>Quetiapine can be administered with or without food.</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u></strong></p><p>Interactions with herbal products have not been established.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory Interactions</u></strong></p><p>There have been reports of false positive results in enzyme immunoassays for methadone and tricyclic antidepressants in patients who have taken quetiapine. Confirmation of questionable immunoassay screening results by an appropriate chromatographic technique is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnant Women: </strong>Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with quetiapine. The safety and efficacy of quetiapine during human pregnancy have not been established. Following some pregnancies in which quetiapine was used, neonatal withdrawal symptoms have been reported. Therefore, quetiapine should only be used during pregnancy if the expected benefits justify the potential risks.</p><p>&nbsp;</p><p><strong>Neonates: </strong>Neonates exposed to antipsychotic drugs including quetiapine during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p><p>Quetiapine should not be used during pregnancy unless the expected benefits to the mother markedly outweigh the potential risks to the fetus.</p><p>&nbsp;</p><p><strong>Nursing Women:</strong></p><p>There have been published reports of quetiapine excretion into human breast milk, however the degree of excretion was not consistent. Women who are breast-feeding should therefore be advised to avoid breast-feeding while taking Quetiapine.</p><p>&nbsp;</p><p><strong>Fertility:</strong></p><p>Effects related to elevated prolactin levels (marginal reduction in male fertility and pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced pregnancy rate) were seen in rats, although these are not directly relevant to humans because of species differences in hormonal control of reproduction.</p><p>&nbsp;</p><p>Quetiapine had no teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential Effect on Cognitive and Motor Performance:</strong></p><p>Somnolence was a very commonly reported adverse event in patients treated with quetiapine, especially during the initial dose titration period. Since quetiapine may cause sedation and impair motor skill, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are reasonably certain that quetiapine therapy does not affect them adversely. Somnolence may lead to falls.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p><p>&nbsp;</p><p><strong><u>Overview of Clinical Trial and Post Market Adverse Drug Reactions</u></strong></p><p>The most commonly reported adverse drug reactions in both clinical trials and during post- marketing experience with quetiapine (&ge;10%) are somnolence dizziness, dry mouth, withdrawal (discontinuation) symptoms, elevations in serum triglyceride levels, elevations in total cholesterol (predominantly LDL cholesterol), decreases in HDL cholesterol, weight gain, decreased haemoglobin and extrapyramidal symptoms.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p>The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The figures cited, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence in the populations studied.</p><p>&nbsp;</p><p><strong>Adverse Events Associated with Discontinuation</strong></p><p><em>Short-Term Placebo-Controlled</em><em> Clinical Trials:</em></p><p><em>Schizophrenia: </em>Overall, 3.9% of quetiapine treated patients (n=510) discontinued treatment due to adverse events compared with 2.9% of placebo-treated patients (n=206). Somnolence, the single most common adverse event leading to withdrawal from quetiapine treatment, led to the withdrawal of four quetiapine-treated patients and no placebo-treated patients. Postural hypotension, hypotension, and/or tachycardia led to withdrawal of 1.8% of quetiapine-treated subjects, compared to 0.5% of placebo-treated subjects.</p><p>&nbsp;</p><p><em>Bipolar</em><em> Disorder:</em></p><p><em>Bipolar Mania: </em>Discontinuations due to adverse events were similar for quetiapine (5.7%) and placebo (5.1%).</p><p>&nbsp;</p><p><em>Combined</em><em> Short- and Long-term Controlled Trial Database in Schizophrenia:</em></p><p>In a premarketing controlled clinical trial database of 1710 quetiapine-treated patients, 5% discontinued due to an adverse event. Somnolence was the single most common adverse event leading to withdrawal of 24 patients from quetiapine, and was the only adverse event leading to withdrawal that occurred in more than 1% of patients. Cardiovascular adverse events (e.g., postural hypotension, hypotension, tachycardia, dizziness) accounted for 20% of all subject withdrawals from quetiapine treatment. Sixteen (0.9%) quetiapine-treated subjects were withdrawn due to elevated liver enzymes. Four quetiapine-treated subjects were withdrawn because of leucopenia. Two of these subjects had at least one clinically significant, non-baseline low neutrophil count. Two quetiapine-treated subjects were withdrawn from the trial because of suspected neuroleptic malignant syndrome (NMS).</p><p>&nbsp;</p><p><strong>Commonly</strong><strong> Observed Adverse Events in Short-Term Placebo-Controlled Clinical Trials </strong></p><p><em>Schizophrenia: </em>The following treatment-emergent adverse events, derived from Table 1, commonly occurred during acute therapy with quetiapine (incidence of at least 5%, and an incidence at least 5% higher than that observed with placebo): somnolence, dizziness, dry mouth, postural hypotension, and elevated ALT levels.</p><p>&nbsp;</p><p><em>Bipolar</em><em> Disorder:</em></p><p><em>Bipolar Mania</em>: In the bipolar mania studies, the following treatment-emergent adverse events commonly occurred during acute therapy with quetiapine (incidence of at least 5%, and an incidence at least 5% higher than that observed with placebo): somnolence, dry mouth, and weight gain.</p><p>&nbsp;</p><p><strong>Incidence of Adverse Events in Placebo-Controlled Clinical Trials</strong></p><p>Certain portions of the discussion below relating to objective or numeric safety parameters are derived from studies in patients with schizophrenia and have not been duplicated for bipolar mania trials. However, this information is also generally applicable to bipolar mania. Table 1 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during acute therapy (up to 6 weeks) of schizophrenia in 1% or more of patients treated with quetiapine (doses of 150 mg/day or more) where the incidence in patients treated with quetiapine was greater than the incidence in placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table</strong><strong> 1&nbsp; Adverse Events Reported for at least 1% Of Quetiapine-Treated Subjects (Dose &ge; 150 mg/day) and for a Higher Percentage of Quetiapine-Treated Subjects than Subjects Who Received Placebo in Short-Term, Placebo- Controlled Schizophrenia Phase II-III Trials</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body system and COSTART Term</strong></p></td><td rowspan="1" colspan="2"><p><strong>Percentage</strong><strong> of</strong><strong> </strong><strong>subjects</strong><strong> </strong><strong>with adverse</strong><strong> events*</strong></p></td></tr><tr><td>&nbsp;</td><td><p>Quetiapine Fumarate</p><p>(n = 449)</p></td><td><p>Placebo</p><p>(n = 202)</p></td></tr><tr><td><p><strong>Whole body</strong></p></td><td><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td><p>Headache</p></td><td><p>20</p></td><td><p>17</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>4</p></td><td><p>1</p></td></tr><tr><td><p>Back pain</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Fever</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Nervous</strong><strong> system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Somnolence</p></td><td><p>18</p></td><td><p>11</p></td></tr><tr><td><p>Dizziness</p></td><td><p>10</p></td><td><p>4</p></td></tr><tr><td><p><strong>Digestive</strong><strong> system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Constipation</p></td><td><p>9</p></td><td><p>5</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>7</p></td><td><p>2</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>6</p></td><td><p>2</p></td></tr><tr><td><p>Gamma glutamyl transpeptidase increased</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Cardiovascular</strong><strong> system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Postural hypotension</p></td><td><p>8</p></td><td><p>2</p></td></tr><tr><td><p>Tachycardia</p></td><td><p>7</p></td><td><p>5</p></td></tr><tr><td><p>Palpitation</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td><p><strong>Metabolic</strong><strong> and nutritional disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>ALT increased</p></td><td><p>7</p></td><td><p>2</p></td></tr><tr><td><p>AST increased</p></td><td><p>4</p></td><td><p>1</p></td></tr><tr><td><p>Weight gain</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Endocrine</strong><strong> system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypothyroidism</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td><p><strong>Skin and appendages</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash</p></td><td><p>4</p></td><td><p>3</p></td></tr><tr><td><p><strong>Respiratory</strong><strong> system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rhinitis</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p><strong>Hemic and lymphatic system</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Leucopenia</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Special</strong><strong> </strong><strong>senses</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear pain</p></td><td><p>1</p></td><td><p>0</p></td></tr></tbody></table><p>* Subjects may have had more than one adverse event.</p><p>&nbsp;</p><p><u>Other Adverse Events</u></p><p>Frequencies are reported as follows: Very common (&ge;10%)</p><p>Common (&ge;1% - &lt;10%)</p><p>Uncommon (&ge;0.1% - &lt;1%)</p><p>Rare (&ge;0.01% - &lt;0.1%)</p><p>&nbsp;</p><p><strong>Weight Gain: </strong>During acute therapy (up to 6 weeks) in placebo-controlled schizophrenia clinical trials, mean weight gain in patients taking quetiapine was 2.3 kilograms compared to a mean weight gain of 0.1 kilograms in patients taking placebo. In open-label extension trials with quetiapine monotherapy, mean weight gain after 9 to 13 weeks was 1.58 kg, after 14 to 26 weeks, 0.26 kg, after 27 to 39 weeks, 1.66 kg, after 40 to 52 weeks, -1.53 kg and after 53 to 78 weeks, 1.98 kg (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism). In the acute placebo-controlled bipolar mania clinical trials (up to 12 weeks) mean weight gain in patients taking quetiapine was 1.8 kg compared to a mean weight loss of 0.1 kg in patients taking placebo. In patients completing the entire 12 weeks of treatment mean weight gain in patients taking quetiapine was 2.8 kg.</p><p>Based on the cumulative acute placebo-controlled clinical trial database, weight gain (based on &ge;7% increase in body weight from baseline) was reported in 9.6% in quetiapine-treated patients and 3.8% in placebo-treated patients, which occurs predominantly during the early weeks of treatment in adults (see WARNINGS AND PRECAUTIONS).</p><p><strong>Seizures: </strong>There have been uncommon reports (&ge;0.1% - &lt;1%) of seizures in patients administered quetiapine, although the frequency was no greater than that observed in patients administered placebo in controlled clinical trials (see WARNINGS AND PRECAUTIONS, Neurologic).</p><p><strong>Restless</strong><strong> Legs Syndrome: </strong>There have been uncommon cases of restless legs syndrome in patients administered quetiapine.</p><p><strong>Priapism: </strong>There have been rare reports (&ge;0.01% - &lt;0.1%) of priapism in patients administered quetiapine.</p><p><strong>Somnolence: </strong>Somnolence may occur, usually during the first two weeks of treatment, which generally resolves with the continued administration of quetiapine.</p><p><strong>Somnambulism: </strong>In rare cases, somnambulism and other related events have been reported.</p><p><strong>Neuroleptic Malignant Syndrome: &nbsp;</strong>As with other antipsychotics, rare cases of neuroleptic malignant syndrome have been reported in patients treated with quetiapine (see WARNINGS AND PRECAUTIONS, Neurologic).</p><p><strong>Hypothermia: </strong>There have been rare cases of hypothermia in patients treated with quetiapine.</p><p><strong>Vital Signs: </strong>As with other antipsychotics with &alpha;1 adrenergic blocking activity, quetiapine may induce postural hypotension, associated with very common cases of dizziness, common cases of tachycardia and, in uncommon cases, some patients may experience syncope especially during the initial dose titration period (see WARNINGS AND PRECAUTIONS, Cardiovascular). In placebo-controlled clinical trials in schizophrenia, postural hypotension was reported with an incidence of 8% in quetiapine-treated patients compared to 2% in placebo-treated patients.</p><p>Quetiapine was associated with a mean baseline to endpoint increase in heart rate of 3.9 beats per minute, compared to 1.6 beats per minute among placebo-treated patients.</p><p><strong>Bradycardia: </strong>Uncommon cases of bradycardia and related events have been reported in patients treated with quetiapine. It may occur at or near initiation of treatment and be associated with hypotension and/or syncope.</p><p><strong>Pancreatitis: </strong>Rare cases of pancreatitis have been reported from a review of all clinical trials with quetiapine.</p><p><strong>Dyspnea: </strong>Common cases of dyspnea often occurred in the setting of tachycardia, dizziness, orthostatic hypotension and/or underlying cardiac/respiratory disease.</p><p><strong>Palpitations: </strong>Common cases of palpitations have occurred in the setting of tachycardia, dizziness, orthostatic hypotension and/or underlying cardiac/respiratory disease.</p><p><strong>Peripheral</strong><strong> Edema: </strong>As with other antipsychotic agents, common cases (&ge;1% - &lt;10%) of peripheral edema have been reported in patients treated with quetiapine.</p><p><strong>Pyrexia: </strong>There have been common cases of pyrexia in patients treated with quetiapine.</p><p><strong>Vomiting: </strong>There have been common cases of vomiting in patients treated with quetiapine although this has been seen more often in elderly patients (&gt;65 years of age).</p><p><strong>Mild Asthenia: </strong>As with other antipsychotic agents, common cases of mild asthenia have been reported in patients treated with quetiapine.</p><p><strong>Rhinitis: </strong>Uncommon cases of rhinitis have been reported.</p><p><strong>Hypersensitivity: </strong>Uncommon cases of hypersensitivity including angioedema have been reported.</p><p><strong>ECG Changes: </strong>Between group comparisons for pooled placebo-controlled trials revealed no statistically significant quetiapine /placebo differences in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc, and PR intervals.</p><p>However, the proportions of patients meeting the criteria for tachycardia were compared in four 3- to 6-week-placebo-controlled clinical trials for the treatment of schizophrenia revealing a 1% (4/399) incidence for quetiapine compared to 0.6% (1/156) incidence for placebo. Quetiapine use was associated with a mean increase in heart rate, assessed by ECG, of 7 beats per minute compared to a mean increase of 1 beat per minute among placebo patients. This slight tendency to tachycardia may be related to the potential of quetiapine for inducing orthostatic changes (see WARNINGS AND PRECAUTIONS, Cardiovascular). In bipolar disorder &nbsp;mania trials, the proportion of patients meeting the criteria for tachycardia was 0.5% (1/192) for quetiapine compared to 0% (0/178) for placebo.</p><p><strong>Tardive Dyskinesia</strong>: There have been uncommon cases of tardive dyskinesia reported in patients administered quetiapine (see WARNINGS AND PRECAUTIONS, Neurologic).</p><p><strong>Extrapyramidal Symptoms (EPS): </strong><u>There have been very common cases of EPS reported.</u> Table 3 enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms in a short-term acute phase clinical trial in patients with schizophrenia comparing five fixed doses of quetiapine with placebo (n = ~ 50 patients per group), as assessed by: 1) spontaneous complaints of parkinsonism (extrapyramidal syndrome, hypertonia, tremor and cogwheel rigidity), or akathisia; 2) Simpson-Angus scores (mean change from baseline); and 3) use of anticholinergic medication to treat emergent EPS.</p><p>&nbsp;</p><p><strong>Table 3 Treatment-Emergent Extrapyramidal Symptoms, Assessed By Spontaneous Reports, Simpson Scale, And Incidence Of Anticholinergic Use</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p>Placebo</p></td><td colspan="5"><p><strong>QUETIAPINE</strong></p></td></tr><tr><td><p>75 mg</p></td><td><p>150 mg</p></td><td><p>300 mg</p></td><td><p>600 mg</p></td><td><p>750 mg</p></td></tr><tr><td><p>Spontaneous Reports of Parkinsonian Symptoms*</p></td><td><p>10%</p></td><td><p>6%</p></td><td><p>4%</p></td><td><p>4%</p></td><td><p>8%</p></td><td><p>4%</p></td></tr><tr><td><p>Spontaneous Reports of Akathisia</p></td><td><p>8%</p></td><td><p>2%</p></td><td><p>2%</p></td><td><p>0%</p></td><td><p>0%</p></td><td><p>2%</p></td></tr><tr><td><p>Simpson Scale</p></td><td><p>-0.6</p></td><td><p>-1.0</p></td><td><p>-1.2</p></td><td><p>-1.6</p></td><td><p>-1.8</p></td><td><p>-1.8</p></td></tr><tr><td><p>Incidence of Anticholinergic Use</p></td><td><p>14%</p></td><td><p>11%</p></td><td><p>10%</p></td><td><p>8%</p></td><td><p>12%</p></td><td><p>11%</p></td></tr></tbody></table><p>*Patients may have had more than one Parkinsonism adverse event</p><p>&nbsp;</p><p>There were no differences between the quetiapine and placebo treatment groups in the incidence of EPS or concomitant use of anticholinergics and no evidence of dose-related increase in EPS or in the use of concomitant anticholinergics across the dose range of 75 &ndash; 750 mg/day.</p><p>&nbsp;</p><p>In 2 bipolar mania placebo-controlled clinical trials using variable doses of quetiapine, there were no differences between the quetiapine and placebo treatment groups in the incidence of EPS, as assessed by Simpson-Angus total scores and Barnes Akathisia rating scale, spontaneous complaints of EPS and the use of concomitant anticholinergic medications to treat EPS.</p><p>&nbsp;</p><p>In short-term placebo-controlled clinical trials in schizophrenia and bipolar mania, the aggregated incidence of EPS-related adverse events was similar to placebo (schizophrenia: 7.8% for quetiapine and 8.0% for placebo; bipolar mania: 11.2% for quetiapine and 11.4% for placebo). In long-term studies of schizophrenia and bipolar disorder the aggregated exposure adjusted incidence of treatment-emergent EPS was similar between quetiapine and placebo. See WARNINGS AND PRECAUTIONS, Neurologic.</p><p>&nbsp;</p><p><strong>Blurred Vision: </strong>There have been common cases of blurred vision in patients administered quetiapine.</p><p><strong>Dysphagia: </strong>There have been uncommon cases of dysphagia in patients administered quetiapine.</p><p><strong>Dysarthria: </strong>There have been common cases of dysarthria in patients administered quetiapine.</p><p><strong>Acute Withdrawal (discontinuation) Symptoms: </strong>Acute discontinuation symptoms such as insomnia, nausea, headache, diarrhea, vomiting, dizziness and irritability, have been described after abrupt cessation of antipsychotic drugs including quetiapine. Gradual withdrawal over</p><p>a period of at least one to two weeks is advisable. Symptoms usually resolved after 1 week post-discontinuation. See WARNINGS AND PRECAUTIONS, General.</p><p><strong>Acute Withdrawal (discontinuation) Symptoms: </strong>Acute discontinuation symptoms such as insomnia, nausea, headache, diarrhea, vomiting, dizziness and irritability, have been described after abrupt cessation of antipsychotic drugs including quetiapine. Gradual withdrawal over a period of at least one to two weeks is advisable. Symptoms usually resolved after 1 week post- discontinuation. See WARNINGS AND PRECAUTIONS, General.</p><p><strong>Abnormal dreams and nightmares: </strong>There have been common cases of abnormal dreams and nightmares in patients administered quetiapine.</p><p>Suicide-related events: In short-term placebo-controlled clinical trials across all indications and ages, the incidence of suicide-related events (suicidal thoughts, self-harm and suicide) was 0.8% for both quetiapine (76/9327) and for placebo (37/4845).</p><p>In these trials of patients with schizophrenia the incidence of suicide-related events was 1.4% (3/212) for quetiapine and 1.6% (1/62) for placebo in patients 18-24 years of age, 0.8% (13/1663) for quetiapine and 1.1% (5/463) for placebo in patients &ge;25 years of age.</p><p>In these trials of patients with bipolar mania the incidence of suicide-related events was 0% for both quetiapine (0/60) and placebo (0/58) in patients 18-24 years of age, 1.2% for both quetiapine (6/496) and placebo (6/503) in patients &ge;25 years of age.</p><p>&nbsp;</p><p><strong>Irritability: </strong>There have been common cases of irritability in patients administered quetiapine.</p><p><strong>Increased appetite: </strong>There have been common cases of increased appetite in patients administered quetiapine.</p><p><strong>Constipation: </strong>Patients should be advised of the risk of severe constipation during quetiapine treatment, and that they should tell their doctor if constipation occurs or worsens, as they may need laxatives<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em>Urinary retention: </strong>There have been uncommon cases of urinary retention in patients administered quetiapine.</p><p><strong>Agranulocytosis: </strong>There have been rare cases of agranulocytosis based on the frequency of patients during all quetiapine clinical trials with severe neutropenia (&lt;0.5 x 109/L) and infection.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p>As with other antipsychotics, common cases of leucopenia and/or neutropenia have been observed in patients administered quetiapine. In clinical trial and post-marketing experience, events of severe neutropenia (&lt;0.5 x 109/L), granulocytopenia and agranulocytosis (severe neutropenia and infection) have been reported during antipsychotic use, including quetiapine (see ACTION AND CLINICAL PHARMACOLOGY). Leucopenia cases were based on shifts from normal baseline to potentially clinically important values at anytime post-baseline in all trials.</p><p>Shifts in white blood cells were defined as &le;3 x 109 cells/L at any time (see WARNINGS AND PRECAUTIONS, Hematologic). Based on shifts (eosinophil shifts were defined as &ge;1 x 109 cells/L at any time) from normal baseline to potentially clinically important values at anytime post-baseline in all trials, common cases of increased eosinophils have been observed.</p><p>Uncommon cases of thrombocytopenia (platelet count decreased, &le;100 X 109/L on at least one occasion) have been observed. Decreased hemoglobin to &le;130 g/L males, &le;120 g/L females on at least one occasion occurred in 11% of quetiapine patients in all trials including open-label extensions. In short-term placebo-controlled trials, decreased hemoglobin to &le;130 g/L males, &le;120 g/L females on at least one occasion occurred in 8.3% of quetiapine patients compared to 6.2% of placebo patients.</p><p>Based on clinical trial adverse event reports not associated with neuroleptic malignant syndrome, rare cases of elevations in blood creatine phosphokinase have been reported in patients administered quetiapine.</p><p>&nbsp;</p><p><strong>Hyperprolactinemia: </strong>Common cases of elevations in serum prolactin levels have been observed (&gt;20 mg/L in males and &gt;30mg/L in females) (see WARNINGS AND PRECAUTIONS, Hyperprolactinemia).</p><p><strong>Neutropenia:</strong><strong> </strong>In all short-term placebo-controlled monotherapy clinical trials among patients with a baseline neutrophil count &ge; 1.5 x 109&nbsp;/L, the incidence of at least one occurrence of neutrophil count &lt; 1.5 x 109 /L was 1.9% in patients treated with quetiapine, compared to 1.5% in placebo-treated patients. The incidence &ge; 0.5 - &lt;1.0 x 109/L was 0.2% in patients treated with quetiapine and 0.2% in placebo-treated patients. In clinical trials conducted prior to a protocol amendment for discontinuation of patients with treatment-emergent neutrophil count &lt;1.0 x 109/L, among patients with a baseline neutrophil count &ge; 1.5 x 109/L, the incidence of at least one occurrence of neutrophil count &lt; 0.5 x 109/L was 0.21% in patients treated with quetiapine and 0% in placebo-treated patients (see WARNINGS AND PRECAUTIONS, Hematologic).</p><p><strong>Transaminase Elevations: </strong>Common cases of asymptomatic elevations (shift from normal to &gt;3 times the upper limits of normal at any time) in serum alanine aminotransferase (ALT) or gamma-GT levels have been observed in some patients administered quetiapine. Uncommon cases of asymptomatic elevations (shift from normal to &gt;3 times the upper limits of normal at any time) in serum aspartate aminotranferase (AST) have been observed in some patients administered quetiapine. These elevations were usually reversible on continued quetiapine treatment (see WARNINGS AND PRECAUTIONS, Hepatic).</p><p><strong>Thyroid: </strong>Quetiapine treatment was associated with dose-related decreases in thyroid hormone levels. Based on shifts (total T4, free T4, total T3 and free T3 &lt;0.8 x LLN (pmol/L) and TSH &gt;5mIU/L at anytime) from normal baseline to a potentially clinically important value at anytime post-baseline in all trials, uncommon cases of decreases in free T3 and common cases of decreases in total T4, free T4 and total T3 as well as increases in TSH have been reported. The following table shows the incidence of these shifts in short-term placebo-controlled clinical trials:</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:465.75pt;height:2in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img alt="" width="687" height="198" src="data:image/jpeg;base64,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" /></p><p>In short-term placebo-controlled monotherapy trials, the incidence of reciprocal, potentially clinically significant shifts in T3 and TSH was 0.0% for both quetiapine and placebo and 0.1% for quetiapine versus 0.0% for placebo for shifts in T4 and TSH. These changes in thyroid hormone levels are generally not associated with clinically symptomatic hypothyroidism. The reduction in total and free T4 was maximal within the first 6 weeks of quetiapine treatment, with no further reduction during long-term treatment. There was no evidence of clinically significant changes in TSH concentration over time. In nearly all cases, cessation of quetiapine treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment. In 8 patients, where TBG was measured, levels of TBG were unchanged (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism).</p><p><strong>Hyperglycaemia: </strong>Blood glucose increases to hyperglycaemic levels (fasting blood glucose &ge;7.0 mmol/L or a non fasting blood glucose &ge;11.1 mmol/L on at least one occasion) have been observed commonly (&ge;1% - &lt;10%) with quetiapine in clinical trials. See WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Hyperglycaemia.</p><p>In 2 long-term bipolar maintenance placebo-controlled adjunct clinical trials, mean exposure 213 days for quetiapine (646 patients) and 152 days for placebo (680 patients), the exposure-adjusted rate of any increased blood glucose level (&ge;7.0 mmol/L) for patients more than 8 hours since a meal was 18.0 per 100 patient years for quetiapine (10.7% of patients) and 9.5 for placebo per 100 patient years (4.6% of patients).</p><p>In short-term (12 weeks duration or less) placebo-controlled clinical trials (3342 treated with quetiapine and 1490 treated with placebo), the percent of patients who had a fasting blood glucose &ge;7.0 mmol/L or a non fasting blood glucose &ge;11.1 mmol/L was 3.5% for quetiapine and 2.1% for placebo.</p><p>In a 24 week trial (active-controlled, 115 patients treated with quetiapine) designed to evaluate glycemic status with oral glucose tolerance testing of all patients, at week 24 the incidence of a treatment-emergent post-glucose challenge glucose level &ge;11.1 mmol/L was 1.7% and the incidence of a fasting treatment-emergent blood glucose level &ge;7.0 mmol/L was 2.6%. See WARNINGS AND PRECAUTIONS, Endocrine and Metabolism.</p><p>&nbsp;</p><p><strong>Cholesterol</strong><strong> and Triglyceride Elevations: </strong>Very common (&ge;10%) cases of elevations in serum triglyceride levels (&ge;2.258 mmol/L on at least one occasion), elevations in total cholesterol (predominantly LDL cholesterol) (&ge;6.2064 mmol/L on at least one occasion), and decreases in HDL cholesterol levels (&lt;1.025 mmol/L males; &lt;1.282 mmol/L females at any time) have been observed during treatment with quetiapine in clinical trials (see WARNINGS AND PRECAUTIONS, Cardiovascular). Lipid increases should be managed as clinically appropriate.</p><p>In one 24-week clinical trial, where LDL cholesterol was directly measured as opposed to calculated, there was a slight mean increase in total cholesterol in patients administered quetiapine, which was driven by increases in LDL cholesterol. The mean LDL level increased at Week 24 by 10% in patients administered quetiapine, which was statistically significant. The total cholesterol/HDL ratio did not change significantly during therapy with quetiapine.</p><p>Furthermore, triglycerides did not increase significantly nor did HDL cholesterol decrease during therapy. See WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Cholesterol and Triglyceride .</p><p>&nbsp;</p><p><strong>Adverse Drug Reactions in Pediatrics (&lt;18 years of age)</strong></p><p>The safety and efficacy of quetiapine in children under the age of 18 years have not been established and its use is not recommended.</p><p>The same adverse drug reactions described above for adults should be considered for children and adolescents. The following table summarizes adverse drug reactions that occur in a higher frequency category in children and adolescents patients (ages 10-17 years) than in the adult population or adverse drug reactions that have not been identified in the adult population, based on data for formulations containing quetiapine (see WARNINGS AND PRECAUTIONS, Special Populations).</p><p><img alt="" width="727" height="629" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p><strong>Weight Gain in Children and Adolescents:</strong></p><p>In one 6-week, placebo-controlled trial in adolescent patients (13-17 years of age) with schizophrenia, the mean increase in body weight, was 2.0 kg in the quetiapine group and -0.4 kg in the placebo group. Twenty one percent of quetiapine treated patients and 7% of placebo- treated patients gained &ge; 7 % of their body weight.</p><p>In one 3-week, placebo-controlled trial in children and adolescent patients (10-17 years of age) with bipolar mania, the mean increase in body weight was 1.7 kg in the quetiapine group and 0.4 kg in the placebo group. Twelve percent of quetiapine treated patients and 0% of placebo-treated patients gained &ge; 7 % of their body weight.</p><p>In the open-label study that enrolled patients from the above two trials, 63% of patients (241/380) completed 26 weeks of therapy with quetiapine. After 26 weeks of treatment, the mean increase in body weight was 4.4 kg. Forty five percent of the patients gained &ge; 7% of their body weight, not adjusted for normal growth. In order to adjust for normal growth over 26 weeks an increase of at least 0.5 standard deviation from baseline in BMI was used as a measure of a clinically significant change; 18.3% of patients on quetiapine met this criterion after 26 weeks of treatment.</p><p>Cumulatively, 17% of quetiapine treated children and adolescents gained &ge; 7% of their body weight versus 2.5% of placebo treated in these studies. In contrast, 9.6% of adults treated with quetiapine gained &ge; 7% of their body weight versus 3.8% of placebo treated based on the cumulative acute placebo-controlled clinical trial database.</p><p>&nbsp;</p><p><strong>Extrapyramidal Symptoms in Children and Adolescent Population:</strong></p><p>Across the placebo-controlled studies, the incidences of adverse events potentially related to extrapyramidal symptoms for adolescents and children in both schizophrenia and bipolar mania were higher in quetiapine treated patients, a finding that was not observed in trials of adults with these indications.</p><p>In a short-term placebo-controlled monotherapy trial in adolescent patients (13-17 years of age) with schizophrenia, the aggregated incidence of extrapyramidal symptoms was 12.9% for quetiapine and 5.3% for placebo, though the incidence of the individual adverse events (e.g., akathisia, tremor, extrapyramidal disorder, hypokinesia, restlessness, psychomotor hyperactivity, muscle rigidity, dyskinesia) was generally low and did not exceed 4.1% in any treatment group. In a short-term placebo-controlled monotherapy trial in children and adolescent patients (10-17 years of age) with bipolar mania, the aggregated incidence of extrapyramidal symptoms was 3.6% for quetiapine and 1.1% for placebo.</p><p>&nbsp;</p><p><strong>Cholesterol and Triglyceride Elevations:</strong></p><p>Very common (&ge;10%) cases of elevations in serum triglyceride levels (&ge;1.69 mmol/L on at least one occasion), elevations in total cholesterol (predominantly LDL cholesterol) (&ge;5.172 mmol/L on at least one occasion) have been observed during treatment with quetiapine in patients &lt;18 years of age in clinical trials.</p><p>&nbsp;</p><p><strong>Increased Blood Pressure:</strong></p><p>In placebo-controlled trials in children and adolescents with schizophrenia (6-week duration) or bipolar mania (3-week duration), the incidence of increases at any time in systolic blood pressure (&ge;20 mmHg) was 15.2% (51/335) for quetiapine and 5.5% (9/163) for placebo; the incidence of increases at any time in diastolic blood pressure (&ge;10 mmHg) was 40.6% (136/335) for quetiapine and 24.5% (40/163) for placebo. In the 26 week open-label clinical trial, one child with a reported history of hypertension experienced a hypertensive crisis.</p><p>&nbsp;</p><p><strong>Suicide Related Events:</strong></p><p>Although not indicated, in clinical trials in patients &lt;18 years of age with schizophrenia, the incidence of suicide-related events was 1.4% (2/147) for quetiapine and 1.3% (1/75) for placebo.</p><p>Although not indicated, in clinical trials in patients &lt;18 years of age with bipolar mania, the incidence of suicide-related events was 1.0% (2/193) for quetiapine and 0% (0/90) for placebo.</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>The following Undesirable effects were identified during post approval use of quetiapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>During post-marketing experience, leucopenia and/or neutropenia have been reported during quetiapine treatment. Resolution of leucopenia and/or neutropenia has followed cessation of therapy with quetiapine. Possible risk factors for leucopenia and/or neutropenia include pre- existing low white cell count and history of drug induced leucopenia and/or neutropenia. In post- marketing reports, there have been cases of agranulocytosis (including fatal cases) in patients administered quetiapine. See WARNINGS AND PRECAUTIONS, Hematologic.</p><p>As with some other antipsychotics, hyperglycaemia and diabetes mellitus (including exacerbation of pre-existing diabetes, diabetic ketoacidosis, and diabetic coma including some fatal cases) in the aggregate have been reported rarely (&ge;0.01% - &lt;0.1%) during the use of quetiapine, sometimes in patients with no reported history of hyperglycaemia. See WARNINGS AND PRECAUTIONS, Endocrine and Metabolism.</p><p>Anaphylactic reactions have been reported very rarely in post-marketing reports, including a case with a fatal outcome, possibly related to quetiapine treatment. The reporting rate of anaphylaxis associated with quetiapine use, which is generally accepted to be an underestimate due to underreporting, does not exceed the background incidence rate estimates. Estimates of the background incidence rate (all cause) of severe life-threatening anaphylaxis in the general population range between 80 and 210 cases per million person-years, and the incidence rate of drug-induced anaphylaxis is reported to be 16 cases per million person-years. In addition, the all cause fatal anaphylaxis rate is reported to be one case per million person-years while the drug-induced fatal anaphylaxis is estimated to be 0.3 cases per million person-years.</p><p>If a patient develops anaphylaxis after treatment with quetiapine, the drug should be discontinued and an alternative treatment started.</p><p>Based on post-marketing reports, galactorrhea has been reported rarely.</p><p>During post-marketing experience, there have been cases of intestinal obstruction (ileus) in patients administered quetiapine. See WARNINGS AND PRECAUTIONS, Gastrointestinal.</p><p>Although there have been post-marketing cases of neonatal withdrawal in mothers administered quetiapine, the frequency is unknown. See WARNINGS AND PRECAUTIONS, Special Populations.</p><p>In post-marketing reports, there have been cases of urinary retention in patients administered quetiapine.</p><p>Other Undesirable effects reported since market introduction, which were temporally related to quetiapine therapy, but not necessarily causally related include the following: rhabdomyolysis, cardiomyopathy, myocarditis and syndrome of inappropriate secretion of antidiuretic hormone (SIADH).</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Experience</u></strong></p><p><strong>Clinical Trials: </strong>One death has been reported in a clinical trial following an overdose of 13, 600 mg of quetiapine alone, however, survival has also been reported in acute overdoses of up to 30, 000 mg of quetiapine. Most patients who overdosed reported no adverse events or recovered fully from the reported events.</p><p><strong>Post-Marketing: </strong>In post-marketing experience, there have been cases of coma and death in patients taking a quetiapine overdose. The lowest reported dose associated with coma has been in a patient who took 5,000 mg and had a full recovery within 3 days. The lowest reported dose associated with a death was in a patient who took 6,000 mg.</p><p>In post-marketing experience, there were cases reported of QT prolongation with overdose. Patients with pre-existing severe cardiovascular disease may be at an increased risk of the effects of overdose (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension and Syncope).</p><p>&nbsp;</p><p><u>Symptoms</u></p><p>In general, reported signs and symptoms were those resulting from an exaggeration of the drug&#39;s known pharmacological effects (e.g., drowsiness and sedation, tachycardia and hypotension).</p><p>&nbsp;</p><p><u>Treatment</u></p><p>There is no specific antidote to quetiapine. In cases of severe intoxication, the possibility of multiple drug involvement should be considered, and intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system. In this context, published reports describe a reversal of severe central nervous system effects, including coma and delirium, with administration of intravenous physostigmine (1-2 mg), under continuous ECG monitoring. If physostigmine salicylate is used, atropine sulfate should be available to reverse excessive cholinergic effects such as bradycardia, marked salivation, emesis and bronchospasm.</p><p>In cases of quetiapine overdose refractory hypotension should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should be avoided, since beta stimulation may worsen hypotension in the setting of quetiapine- induced alpha blockade).</p><p>Close medical supervision and monitoring should be continued until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Quetiapine, a dibenzothiazepine derivative, is an antipsychotic agent. Quetiapine and the active plasma metabolite,&nbsp; norquetiapine interact with a broad range of neurotransmitter receptors. The extent to which the norquetiapine metabolite contributes to the pharmacological activity of quetiapine is not known.</p><p>&nbsp;</p><p><strong>Quetiapine: </strong>Quetiapine exhibits affinity for brain serotonin 5HT2 and 5HT1A receptors (in vitro, Ki = 288 and 557 nM, respectively), and dopamine D1 and D2 receptors (in vitro, Ki = 558 and 531 nM, respectively). It is this combination of receptor antagonism with a higher selectivity for 5HT2 relative to D2 receptors, which is believed to contribute to the clinical antipsychotic properties and low extrapyramidal symptoms (EPS) liability of quetiapine compared to typical antipsychotics. Quetiapine also has high affinity for histamine H1 receptors (in vitro, Ki = 10 nM) and adrenergic &alpha;1 receptors (in vitro, Ki = 13 nM), with a lower affinity for adrenergic &alpha;2 receptors (in vitro, Ki = 782 nM), but no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors and at the norepinephrine reuptake transporter (NET).</p><p>&nbsp;</p><p><strong>Norquetiapine: </strong>Norquetiapine similar to quetiapine, exhibits affinity for brain serotonin 5HT2 and 5HT1A receptors (<em>in</em><em> vitro</em>, Ki = 2.9 nM and 191 nM, respectively), and dopamine D1 and D2 receptors (<em>in</em><em> vitro</em>, Ki = 42 nM and 191 nM respectively). Additionally, like quetiapine, norquetiapine also has high affinity at histaminergic and adrenergic &alpha;1 receptors, with a lower affinity at adrenergic &alpha;2 receptors. Contrary to quetiapine, norquetiapine exhibits high affinity for NET and has moderate to high affinity for several muscarinic receptor subtypes.</p><p>&nbsp;</p><p>Inhibition of NET and partial agonist action at 5HT1A sites by norquetiapine may contribute to the therapeutic efficacy of quetiapine as an antidepressant; however, the clinical relevance of these interactions has not been established. Although affinity at 5HT2B has been observed for norquetiapine, norquetiapine is found to be an antagonist and not an agonist at the receptor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of quetiapine and norquetiapine are linear within the clinical dose range. The kinetics of quetiapine are similar in men and women, and smokers and nonsmokers.</p><p>&nbsp;</p><p><strong>Absorption: </strong>Quetiapine is well absorbed following oral administration. In studies with radiolabelled drug, approximately 73% of the total radioactivity is recovered in the urine and 21% in the faeces over a period of one week. The bioavailability of quetiapine is marginally affected by administration with food, with Cmax&nbsp;and AUC values increased by 25% and 15%, respectively. Peak plasma concentrations of quetiapine generally occur within 2 hours after oral administration. Steady-state peak molar concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.</p><p><strong>Distribution: </strong>Quetiapine has a mean apparent volume of distribution of 10&plusmn;4 L/kg, and is approximately 83% bound to plasma proteins.</p><p><strong>Elimination and Metabolism: </strong>The elimination half-life of quetiapine is approximately 6-7 hours upon multiple dosing within the proposed clinical dosage range. The elimination half-life of norquetiapine is approximately 12 hours. The average molar dose fraction of free quetiapine and the active human plasma metabolite norquetiapine is &lt;5% excreted in the urine.</p><p>Quetiapine is extensively metabolized by the liver, with parent compound accounting for less than 5% of the dose in the urine and faeces, one week following the administration of radiolabelled quetiapine. Since quetiapine is extensively metabolised by the liver, higher plasma levels are expected in the hepatically impaired population, and dosage adjustment may be needed in these patients.</p><p>Major routes of metabolism of quetiapine involve oxidation of the alkyl side chain, hydroxylation of the dibenzothiazepine ring, sulphoxidation, and phase 2 conjugation. The principal human plasma metabolites are the sulfoxide, and the parent acid metabolite, neither of which are pharmacologically active.</p><p>In vitro investigations established that CYP 3A4 is the primary enzyme responsible for cytochrome P450-mediated metabolism of quetiapine. Norquetiapine is primarily formed and eliminated via CYP3A4.</p><p>Quetiapine and several of its metabolites (including norquetiapine) were found to be weak inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro. In vitro CYP inhibition is observed only at concentrations approximately 5 to 50-fold higher than those observed at a dose range of 300 to 800 mg/day in humans.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Geriatrics</strong><strong> (</strong>&ge; <strong>65 years of age): </strong>The mean clearance of quetiapine in the elderly is approximately 30 to 50% of that seen in adults aged 18-65 years (see WARNINGS AND PRECAUTIONS, Special Populations and DOSAGE AND ADMINISTRATION).</p><p><strong>Hepatic Impairment: </strong>In 8 cirrhotic subjects with mild hepatic impairment, administration of a single 25 mg (sub-clinical) oral dose of quetiapine resulted in a 40% increase in both AUC and Cmax. Clearance of the drug decreased by 25% whereas t&frac12; was elevated by nearly 45%.</p><p>Therefore, quetiapine should be used with caution in patients with mild hepatic impairment, especially during the initial dosing period. No pharmacokinetic data are available for any dose of quetiapine in patients with moderate or severe hepatic impairment (see WARNINGS AND PRECAUTIONS, Hepatic and DOSAGE AND ADMINISTRATION).</p><p><strong>Renal Impairment: </strong>At single low (sub-clinical) doses, the mean plasma clearance of quetiapine was reduced by approximately 25% in subjects with severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m2). However, the individual clearance values remained within the range observed for healthy subjects (see WARNINGS AND PRECAUTIONS, Renal and DOSAGE AND ADMINISTRATION).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Thyroid</u></strong></p><p>Quetiapine caused a dose-related increase in pigment deposition in thyroid gland in rat toxicity studies which were 4 weeks in duration or longer and in a mouse 2 year carcinogenicity study. Doses were 10-250 mg/kg in rats, 75-750 mg/kg in mice; these doses are 0.1-3.0, and 0.1-4.5 times the maximum recommended human dose (on a mg/m2&nbsp;basis), respectively. Pigment deposition was shown to be irreversible in rats. The identity of the pigment could not be determined, but was found to be co-localized with quetiapine in thyroid gland follicular epithelial cells. The functional effects and the relevance of this finding to human risk are unknown.</p><p>&nbsp;</p><p><strong><u>Cataracts</u></strong></p><p>In dogs receiving quetiapine for 6 or 12 months, but not for 1 month, focal triangular cataracts occurred at the junction of posterior sutures in the outer cortex of the lens at a dose of 100 mg/kg, or 4 times the maximum recommended human dose on a mg/m2&nbsp;basis. This finding may be due to inhibition of cholesterol biosynthesis by quetiapine. Quetiapine caused a dose related reduction in plasma cholesterol levels in repeat-dose dog and monkey studies; however, there was no correlation between plasma cholesterol and the presence of cataracts in individual dogs. The appearance of delta-8-cholestanol in plasma is consistent with inhibition of a late stage in cholesterol biosynthesis in these species. There also was a 25% reduction in cholesterol content of the outer cortex of the lens observed in a special study in quetiapine treated female dogs.</p><p>Drug-related cataracts have not been seen in any other species; however, in a 1-year study in monkeys, a striated appearance of the anterior lens surface was detected in 2/7 females at a dose of 225 mg/kg or 5.5 times the maximum recommended human dose on a mg/m2&nbsp;basis.</p><p>&nbsp;</p><p><strong><u>Acute Toxicity</u></strong></p><p>Single dose studies were conducted in mice and rats by the oral and intraperitoneal routes and in dogs by the oral route. The principal clinical signs in mice, rats and dogs of decreased motor activity, ptosis, loss of righting reflex, tremors, ataxia, prostration and convulsions were consistent with the pharmacological activity of the drug. The lowest oral doses causing lethality were 250 mg/kg in mouse and 500 mg/kg in rat; no deaths occurred at the highest oral dose tested (750 mg/kg) in dogs. The highest parenteral non-lethal doses were 100 mg/kg in both mouse and rat.</p><p>&nbsp;</p><p><strong><u>Subacute/Chronic Toxicity</u></strong></p><p>In multiple dose studies in rats, dogs and monkeys (refer to Table 5 for individual study details) anticipated central nervous system effects of an antipsychotic drug were observed with quetiapine (e.g., sedation at lower doses and tremor, convulsions or prostration at higher exposures).</p><p>Hyperprolactinaemia, induced through the dopamine D2&nbsp;receptor antagonist activity of quetiapine or its metabolites, varied between species, but was most marked in the rat. A range of effects consequent to this were seen in the 12 month study including mammary hyperplasia, increased pituitary weight, decreased uterine weight and enhanced growth of females.</p><p>Reversible morphological and functional effects on the liver, consistent with hepatic enzyme induction, were seen in mouse, rat and monkey.</p><p>Thyroid follicular cell hypertrophy and concomitant changes in plasma thyroid hormone levels occurred in rat and monkey.</p><p>Pigmentation of a number of tissues, particularly the thyroid, was not associated with any morphological or functional effects.</p><p>Transient increases in heart rate, unaccompanied by an effect on blood pressure, occurred in dogs.</p><p>Posterior triangular cataracts seen after 6 months in dogs at 100 mg/kg/day were consistent with inhibition of cholesterol biosynthesis in the lens. No cataracts were observed in cynomolugus monkeys dosed up to 225 mg/kg/day, or in rodents. Monitoring in clinical studies did not reveal drug-related corneal opacities in man.</p><p>No evidence of neutrophil reduction or agranulocytosis was seen in any of the toxicity studies.</p><p>&nbsp;</p><p><strong><u>Carcinogenicity</u></strong></p><p>Results from the 2 year carcinogenicity studies performed in mice and rats (and mouse sighting studies) are summarized in Table 6.</p><p>In the rat study (doses 0, 20, 75 and 250 mg/kg/day) the incidence of mammary adenocarcinomas was increased at all doses in female rats, consequential to prolonged hyperprolactinaemia.</p><p>In male rat (250 mg/kg/day) and mouse (250 and 750 mg/kg/day), there was an increased incidence of thyroid follicular cell benign adenomas, consistent with known rodent-specific mechanisms resulting from enhanced hepatic thyroxine clearance.</p><p>&nbsp;</p><p><strong>Table 5 Principal Multiple Dose Toxicity Studies With Quetiapine</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Species/Strain</strong></p></td><td><p><strong>Route</strong></p></td><td><p><strong>Study</strong><strong> </strong><strong>Duration</strong></p></td><td><p><strong>Number/</strong><strong> </strong><strong>Group/Sex</strong></p></td><td><p><strong>Dose (mg/kg/day)</strong></p></td><td><p><strong>Salient</strong><strong> </strong><strong>Observations</strong></p></td></tr><tr><td><p>Rat</p><p>Hla:(SD)/BR</p></td><td><p>oral gavage</p></td><td><p>4 weeks dosing and 4 weeks withdrawal</p></td><td><p>14</p></td><td><p>0</p><p>25</p><p>50</p><p>150</p></td><td><p>Ptosis at all doses. Body weight gain decreased at 150 mg/kg/day. Liver weight was increased and uterus, spleen and pituitary weights were decreased in all dose groups. Epididymis and heart weight was decreased at 150 mg/kg/day. Deciduoma-metrial gland changes at 50 mg/kg/day.</p></td></tr><tr><td><p>Rat Hla:(SD)BR</p></td><td><p>oral gavage</p></td><td><p>6 months dosing and 4 weeks withdrawal</p></td><td><p>29</p></td><td><p>0</p><p>25</p><p>50</p><p>150</p></td><td><p>Ptosis at all doses. Reduced body weight gain at 50 mg/kg/day and 150 mg/kg/day. Plasma TSH increased and T3 reduced at 150 mg/kg/day. Pigment deposition and hypertrophy of thyroid follicular cells at 50 mg/kg/day and 150 mg/kg/day. In all dose groups, mammary gland hypertrophy/hyperplasia, atrophy and/or mucification of cervical/vaginal mucosa. Liver weight increased at all doses with hepatocellular vacuolation at 150 mg/kg/day. No adverse-effect dose level was 25 mg/kg.</p></td></tr><tr><td><p>Rat Crl:(WI)BR</p></td><td><p>oral gavage</p></td><td><p>12 months of dosing then 5 weeks withdrawal</p></td><td><p>20</p></td><td><p>0</p><p>10</p><p>25</p><p>75</p><p>250</p></td><td><p>Hypoactivity and hyperprolactinaemia and sequelae (all doses). 27% decrement in body weight gain (250 mg/kg/day). Liver enlargement (75 and 250 mg/kg/day), hepatocyte fat vacuolation (dose related) and centrilobular hypertrophy with increased expression of CYP2B1/2 and CYP3A at 250 mg/kg/day. Increased TSH and T4 and thyroid follicular cell hypertrophy (250 mg/kg/day). Thyroid pigmentation (all doses). Adrenal cortical &nbsp;vacuolation (75 mg/kg/day and above). Increased pancreatic glucagon secreting cells (75 mg/kg/day and above). Increased alveolar macrophages (75 &nbsp;mg/kg/day and above).</p></td></tr><tr><td><p>Dog Beagle</p></td><td><p>oral tablets</p></td><td><p>4 weeks</p></td><td><p>3</p></td><td><p>0</p><p>25</p><p>50</p><p>100</p></td><td><p>Decreased motor activity, ataxia, somnolence, miosis, increased heart rate and hypothermia were observed for animals in all compound-treated groups. In general the incidence was dose-related and decreased with time. All effects reversed on withdrawal.</p></td></tr><tr><td><p>Dog Beagle</p></td><td><p>oral tablets</p></td><td><p>6 months dosing and 8 weeks withdrawal</p></td><td><p>3 or 4</p></td><td><p>0</p><p>25</p><p>50</p><p>100</p></td><td><p>Up to 8 weeks transient sedation and increased heart rate. Dose-related &nbsp;decreases in body weight gain. At 100 mg/kg/day 13-26% decrease in plasma cholesterol and prominent posterior Y sutures, swelling of lens fiber tips and 3/8 females with cataracts; 1 epileptiform seizure, 4/8 muscular twitching. 50 mg/kg/day was the no adverse-effect dose level.</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Species/Strain</strong></p></td><td><p><strong>Route</strong></p></td><td><p><strong>Study</strong><strong> </strong><strong>Duration</strong></p></td><td><p><strong>Number/</strong><strong> </strong><strong>Group/Sex</strong></p></td><td><p><strong>Dose (mg/kg/day)</strong></p></td><td><p><strong>Salient</strong><strong> </strong><strong>Observations</strong></p></td></tr><tr><td><p>Dog Beagle</p></td><td><p>oral tablets</p></td><td><p>12 months dosing and 8 weeks withdrawal</p></td><td><p>4z</p></td><td><p>0</p><p>10</p><p>25</p><p>50</p><p>100</p></td><td><p>Sedation, miosis, abnormal gait and muscular tremors occurred at doses of 25 mg/kg/day and above, mainly in the first 10 weeks. Cataracts in animals given 100 mg/kg/day. Histopathological lenticular changes in 5/8 dogs given 50 mg/kg/day. At 100 mg/kg/day 13/14 dogs showed histological lenticular alterations, consistent with the ophthalmological observations. Fine brown granules in the epithelial cells of the lacrimal glands at all doses.</p></td></tr><tr><td><p>Cynomolgus monkey</p></td><td><p>oral gavage</p></td><td><p>13 months</p></td><td><p>4</p></td><td><p>0, rising dose for 4 weeks with one week at each dose level then 43.5 for 52 weeks</p></td><td><p>Signs of sedation from week 2, duration and severity increased with dose. 43.5 mg/kg/day was considered to be the maximum tolerated dose. Abnormal &nbsp;&nbsp;staring behaviour in 2 animals. Plasma prolactin reduced. No compound-related histopathological changes. No effect on plasma cholesterol. No ophthalmological changes were observed.</p></td></tr><tr><td><p>Cynomolgus monkey</p></td><td><p>oral gavage</p></td><td><p>14 weeks</p></td><td><p>3</p></td><td><p>6, 12, 24, 36, 48, 60, 84, 108, 132, 150, 180, 225, 285 and 350. Rising doses administered 3 doses/day. One week at each dose level</p></td><td><p>Sedation from 24 mg/kg/day, after which the duration and severity increased with dose, until at 225 mg/kg/day prostration occurred. Doses at 285 and 350 mg/kg/day caused reduction in body weight and food consumption, ataxia, increased incidence of prostration and one animal died at 350/mg/kg/day.</p><p>Reductions in red blood cell parameters, plasma bilirubin, cholesterol (20-40% at 285 mg/kg) and ALP activity. No compound-related histopathological changes.</p></td></tr><tr><td><p>Cynomolgus monkey</p></td><td><p>oral gavage</p></td><td><p>56 weeks dosing 4 weeks withdrawal</p></td><td><p>4</p></td><td><p>0, rising dose for 4 weeks then 25, 100 and 225 mg/kg/day administered as 3 doses/day</p></td><td><p>Dose-related incidence and severity of behavioural changes. No abnormal signs on drug withdrawal. 40-60% reduction in plasma cholesterol at 225 mg/kg/day with delta-8-cholestanol present at 15% of cholesterol level at 100 and 225 mg/kg/day. No lens opacities. Minor lens changes at all doses with no lens pathology. Transient elevation of prolactin and mild mammary gland hyperplasia (in males) and T3 levels reduced and mild thyroid follicular cell hypertrophy at 100 and 250 mg/kg/day. Red cell indices reduced and liver enlargement with hepatocyte hypertrophy and fat deposition at 250 mg/kg/day.</p></td></tr></tbody></table><p><strong>Table 6 Carcinogenicity (And Mouse Sighting) Studies With Quetiapine</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Species/Strain</strong></p></td><td><p><strong>Route</strong></p></td><td><p><strong>Study</strong><strong> </strong><strong>Duration</strong></p></td><td><p><strong>Number/</strong><strong> </strong><strong>Group/Sex</strong></p></td><td><p><strong>Dose (mg/kg/day)</strong></p></td><td><p><strong>Salient</strong><strong> </strong><strong>Observations</strong></p></td></tr><tr><td><p>Mouse C57BL/ 10jfCD/1/Alpk</p></td><td><p>oral in diet</p></td><td><p>90 days</p></td><td><p>25</p></td><td><p>0, 50, 100, 200,</p><p>300, 400</p></td><td><p>Reductions in body weight at 100 mg/kg or greater. Seminiferous tubular atrophy severity increased at 100 mg/kg and above.</p><p>Centrilobular hepatocyte enlargement at 200 mg/kg and above. At 50 mg/kg the only effect was an increase in liver weight in females.</p></td></tr><tr><td><p>Mouse C57BL/ 10jfCD/1/Alpk</p></td><td><p>oral in diet</p></td><td><p>90 days</p></td><td><p>15</p></td><td><p>0, 300-800, 400-</p><p>1, 100 (Rising dose maximal at 6 weeks)</p></td><td><p>Reduced body weight, liver weight increase and hepatocyte hypertrophy in both dose groups. Ovary weight decreased in high dose females and testicular weight decreased in low and high dose males. Low and high dose females had dose related decreases in number of corpora lutea. The parotid salivary gland had dose-related increased basophilia. Males had dose-related seminiferous tubular atrophy. Urinary bladder hyaline droplets and pigmentation in the epithelium in both groups.</p></td></tr><tr><td><p>Mouse C57BL/ 10jfCD/1/Alpk</p></td><td><p>oral in diet</p></td><td><p>2 years</p></td><td><p>100, 50, 50,</p><p>50, 50</p></td><td><p>0, 20, 75, 250,</p><p>750 (Rising dose maximal at</p><p>6 weeks)</p></td><td><p>Thyroid follicular cell hypertrophy and pigmentation. Increased incidence of thyroid follicular cell benign adenomas (incidence of 0%, 0%, 0%, 8% and 58% in males only at 0, 20, 75, 250 and 750 mg/kg/day, respectively). No other increases in tumour incidence.</p><p>Other non-neoplastic changes similar to sighting studies.</p></td></tr><tr><td rowspan="2" colspan="1"><p>Rat/Crl:(WI)BR</p><p>&nbsp;</p></td><td rowspan="2" colspan="1"><p>oral&nbsp;gavage</p><p>&nbsp;</p></td><td rowspan="2"><p>2 years</p></td><td rowspan="2"><p>100</p><p>50</p><p>50</p><p>50</p><p>50</p></td><td rowspan="2"><p>0</p><p>20</p><p>75</p><p>250</p></td><td rowspan="2"><p>Increased incidence of mammary adenocarcinomas in all groups of females (incidence of 10%, 26%, 22% and 32% in females given 0, 20, 75 and 250 mg/kg/day respectively). Increased incidence of follicular adenoma of the thyroid gland in males, but not females, given 250 mg/kg/day (incidence of 6%, 6%, 0% and 32% in males given 0, 20, 75 and 250 mg/kg/day respectively). Significant reductions in subcutaneous fibromas, thyroid parafollicular cell adenomas, uterine stromal polyps and carcinoma of the oral cavity.</p></td></tr></tbody></table><p><strong><u>Reproduction and Teratology</u></strong></p><p>Effects related to elevated prolactin levels (marginal reduction in male fertility and pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced pregnancy rate) were seen in rats, although these are not directly relevant to humans because of species differences in hormonal control of reproduction.</p><p>Quetiapine had no teratogenic effects.</p><p>&nbsp;</p><p><strong><u>Mutagenicity</u></strong></p><p>Genetic toxicity studies with quetiapine show that it is not a mutagen or a clastogen. There was no evidence of mutagenic potential in reverse (<em>Salmonella</em><em> typhimurium </em>and <em>E. coli</em>) or forward point mutation (CHO-HGPRT) assays or in two assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenesis assay and the rat bone marrow erythrocyte micronucleus assay).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td><p>Croscarmellose Sodium</p></td></tr><tr><td><p>Colloidal Silicon Dioxide</p></td></tr><tr><td><p>Fumaric Acid</p></td></tr><tr><td><p>Ethyl cellulose N7FP</p></td></tr><tr><td><p>Magnesium Stearate</p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910</p></td></tr><tr><td><p>Hydroxypropyl Cellulose Type LF</p></td></tr><tr><td><p>Polyethylene Glycol 8000</p></td></tr><tr><td><p>Titanium Dioxide</p></td></tr><tr><td><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SERCAND should be stored below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>SERCAND 25 mg</u></p><p><strong><u>Blister</u></strong></p><p><strong>Primary packaging:</strong></p><p><u>Film PVC/PVDC: </u>Clear, transparent plastic film, smooth on both sides. Approximately 205 mm</p><p><u>Foil Silver Plain: </u>Dull silver on one side, shiny silver on the other. Rolled material approximately 205 mm wide</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p><p>&nbsp;</p><p><strong><u>Bottle</u></strong></p><p>Bottle: White, opaque, HDPE round bottle (75cc), 38 mm</p><p>Cap: 38 mm-400, blue polypropylene cap with Lift &ldquo;n&rdquo; Peel tab</p><p>Secondary packaging: NA</p><p>&nbsp;</p><p><u>SERCAND 100 mg</u></p><p><strong><u>Blister</u></strong></p><p><strong>Primary packaging:</strong></p><p><u>Film PVC/PVDC: </u>Clear, transparent plastic film, smooth on both sides. Approximately 205 mm</p><p><u>Foil Silver Plain: </u>Dull silver on one side, shiny silver on the other. Rolled material approximately 205 mm wide</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p><p>&nbsp;</p><p><strong><u>Bottle</u></strong></p><p>Bottle: White, opaque, HDPE round bottle (75cc), 38 mm</p><p>Cap: 38 mm-400, blue polypropylene cap with Lift &ldquo;n&rdquo; Peel tab</p><p>Secondary packaging: NA</p><p>&nbsp;</p><p><u>SERCAND 200 mg</u></p><p><strong><u>Blister</u></strong></p><p><strong>Primary packaging</strong></p><p><u>Film PVC/PVDC: </u>Clear, transparent plastic film, smooth on both sides. Approximately 205 mm</p><p><u>Foil Silver Plain: </u>Dull silver on one side, shiny silver on the other. Rolled material approximately 205 mm wide</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p><p>&nbsp;</p><p><strong><u>Bottle</u></strong></p><p>Bottle: White, opaque, HDPE round bottle (75cc), 38 mm</p><p>Cap: 38 mm-400, blue polypropylene cap with Lift &ldquo;n&rdquo; Peel tab</p><p>Secondary packaging: NA</p><p>&nbsp;</p><p><u>SERCAND 300 mg</u></p><p><strong><u>Blister</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Primary packaging</strong></p><p><u>Film PVC/PVDC: </u>Clear, transparent plastic film, smooth on both sides. Approximately 205 mm</p><p><u>Foil Silver Plain: </u>Dull silver on one side, shiny silver on the other. Rolled material approximately 205 mm wide</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p><p>&nbsp;</p><p><strong><u>Bottle</u></strong></p><p>Bottle: White, opaque, HDPE round bottle (120cc), 38 mm</p><p>Cap: 38 mm-400, blue polypropylene cap with Lift &ldquo;n&rdquo; Peel tab</p><p>Secondary packaging: NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>